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ABSTRACT 
Coronaviruses (CoV) are large enveloped RNA viruses of animals and humans associated 
mostly with enteric and respiratory diseases. These viruses were earlier considered more of a 
veterinary interest and were associated to humans with mild flu. The last decade brought 
outbreaks with high mortality rates caused by CoV transmission from animals to man. This 
remarkable cross-species transmission potential is related to CoV adaptation to a variety of 
cell surface molecules for entry into host cells. The CoV particles bear exposed spike (S) 
proteins in their envelope that attach to specific cell entry receptors, which determines CoV 
host cell range and tropism. CoV can recognize diverse entry receptors, but they 
preferentially use membrane bound ectoenzymes. A subset of CoV recognizes the cell 
surface aminopeptidase N (APN), a membrane-bound metalloprotease.  
APN (CD13) is a “moonlighting” ectoenzyme linked to multiple functions such as 
angiogenesis, cell-cell adhesion and tumorogenesis. It cleaves neutral amino acid side chains 
from the N-terminus of oligopeptides, it is distributed in wide variety of tissues its expression 
is dysregulated in tumors. APN is an important target for cancer therapies and anti-
inflammatory drug design, as well as a major CoV entry receptor. 
This Thesis presents an extensive structural study on mammalian APN ectodomains as well 
as its function as CoV receptor. APN crystal structures revealed ectodomain architecture, 
dimerization and motions important for peptide hydrolysis and CoV recognition. Allosteric 
inhibition of APN catalysis can be mediated by the suppression of APN movements. 
Moreover, the crystal structure of a porcine CoV spike fragment bound to the pig APN 
(pAPN) ectodomain uncovers how CoV bind to its APN receptor. A protruding receptor-
binding edge in the S penetrates in small APN cavities, a receptor-binding mode distinct from 
other CoV-receptor interactions. CoV specifically bind to the open APN conformation. 
Structure-guided studies identified key virus and receptor motifs at the CoV-APN binding 
interface and they show that the receptor-binding region is a major antigenic determinant in 
CoV binding to APN. CoV neutralizing antibodies target key receptor-binding residues, 
showing that they prevent CoV binding to the APN receptor and infection. 
The Thesis provides a compelling view on CoV cell entry and neutralization, as well as 
important structural insights to understand the multifunctional APN protein. 
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RESUMEN  
Los coronavirus (CoV) son virus ARN con envuelta responsables de enfermedades entéricas 
y respiratorias en animales y humanos. Estos virus fueron inicialmente considerados de 
interés veterinario y se asociaron con resfriados en humanos. La última década trajo 
infecciones de CoV con altas tasas de mortalidad, causadas por la transmisión de CoV 
animales a humanos. Este potencial de transmisión transversal entre especies está relacionado 
con la adaptación CoV al uso de diferentes moléculas de la superficie celular para la entrada 
en la célula huésped. Las partículas CoV contienen espículas (S) expuestas en la envuelta que 
adhieren las particulas virales a receptores para su penetración en la célula, que determina el 
tipo de células permisivas para CoV y su tropismo. Los CoV pueden reconocer diversos 
receptores para la entrada, pero preferentemente utilizan ectoenzimas. Un grupo de CoV 
reconoce la aminopeptidasa N (APN), una metaloproteasa unida a la membrana celular.  
APN (CD13) es una ectoenzima que se ha relacionado múltiples funciones, tales como la 
angiogénesis, la adhesión célula-célula y la tumorogénesis. Esta proteína hidroliza 
aminoácidos N-terminales neutros en oligopéptidos, se encuentra en gran variedad de tejidos 
y su expresión aumenta en tumores. APN es una diana importante de terapias contra el cáncer 
y de fármacos anti-inflamatorios, así como un receptor para la entrada CoV en la célula.  
Esta tesis presenta un extenso estudio estructural sobre los ectodominios de APN de 
mamíferos, así como sobre su función como receptor de CoV. Las estructuras cristalográficas 
de la APN revelaron la arquitectura modular de su ectodominio, dimerización y los 
movimientos del mismo, importantes para la catálisis y el reconocimiento de CoV. Se 
muestra la posible inhibición alostérica de la actividad catalítics de la APN mediante la 
supresión de los cambios conformacionales de la APN. Asimismo, la estructura 
cristalográfica de un fragmento de la espícula de un CoV porcino unido al ectodominio de la 
APN de cerdo, han identificado cómo los CoV se unen a su receptor. Una región expuesta en 
la proteína S del CoV penetra en pequeñas cavidades de la APN; este modo de unión al 
receptor es distinto de otras interacciones CoV-receptor descritas. Los CoV se unen 
específicamente a la conformación abierta de la APN. Estudios funcionales identificaron 
motivos clave para la unión del virus y receptor y muestran que la región de unión al receptor 
es un determinante antigénico en CoV, reconocido por anticuerpos neutralizantes, que 
inhiben la unión de los CoV a la APN y la infección. La Tesis proporciona una visión general 
sobre la entrada de CoV en el huésped y su neutralización, así como importantes puntos de 
vista estructurales para comprender las múltiples funciones de la APN.
XIV 
 
  
 
 
 
 
CHAPTER 1 
 
 
 
 
 
 
 
 
 
3 
 
1. INTRODUCTION 
1.1 Viruses  
Viruses are the smallest (with exceptions), most abundant and highly diversified biological 
entities which can infect specifically (with exceptions) almost every life form, whether plant, 
bacteria, animals, or archaea. Nonliving, until a suitable living host is chosen, where is when 
they fit in the definition of a life form, and continue following the propensities of a living 
civilization i.e. to grow, multiply, and proliferate to long distances.  
Viral infection is a complex multi-step phenomenon under which a virus recognizes and 
attaches to the host, invades and releases its progenies. In most viruses, recognition and 
attachment is triggered by the interaction between viral anchors and target host cell 
membrane receptors. Viral tissue tropism and host range are upgraded evolutionarily by 
„specificity switching’ of virus-receptor complexes (Stehle and Casasnovas, 2009), which 
paves the way to more evolved strains with multiple infection mechanisms and broadened 
host coverage. Due to this ability to self-engineer, which favors their mechanistic remodeling, 
that the viral outbreaks are inevitably uncontrollable. The situation becomes graver when 
these smallest biological entities gallop their way through cross-species barriers by virtue of 
their remodeled tropism backed by specificity-switching. This has kept viruses shameless and 
medical research communities puzzled. 
1.2 Coronaviruses (CoV) 
The Coronaviridae is a large family of enveloped, positive single stranded RNA viruses with 
27-32kb genome which imparts a high degree of genome plasticity and in part, adaptability 
and diversity to CoV. Spherical coronavirions (120-160 nm across) appear as peculiar crowns 
due to the presence of spike glycoproteins (Masters, 2006). They have a distinct replication 
mode that by use of template switching mechanism of transcription produces a set of sub-
genomic mRNAs (Masters, 2006). 
From human disease view scope, coronavirus studies were initially regarded as „virology 
backwaters‟ (Cavanagh, 2005) and were more of veterinarians´ interest due to fatal diseases 
in animals associated mostly with meat and dairy supplies or domestics purposes. Human 
CoV infections form HCoV-229E and HCoV-OC43 only caused mild cough and fever. With 
the severe acquired respiratory syndrome (SARS) epidemic in 2003, the CoV gathered 
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spotlights from research communities hailing from almost all realms of disease biology. 
Following SARS, two more human CoV (HCoV) namely HCoV-HKU1 and HCoV-NL63 
were identified. The current scenario projects CoV as important pathogens of animals 
(including humans) that cause enteric, respiratory, neuronal and/or hepatic diseases incurring 
heavy economic losses (Perlman, 1998, Weiss and Navas-Martin, 2005 , Masters, 2006, 
Enjuanes et al., 2008) and high mortalities as has been seen during SARS outbreaks a decade 
earlier (Perlman and Netland, 2009) and recently from the Middle east respiratory syndrome 
(MERS) (de Groot et al., 2013). 
 
 
 
Figure 1.1. Phylogenetic relationship among CoV. A rooted neighbor-joining tree generated from amino acid 
alignments of Coronaviridae-wide conserved domains in replicase polyprotein 1ab of 21 CoV. Each of these is 
representative of a currently recognized CoV species; Equine torovirus Berne served as the out-group. Virus 
names are given with strain specifications; species and genus names are in italics as per convention. The tree 
shows the four main color coded monophyletic clusters, respective to genera Alpha-, Beta-, Gamma-, and 
Deltacoronavirus. Also indicated are Beta-CoV lineages A through D (corresponding to former CoV subgroups 
2A through D). Bootstrap values (1,000 replicates) are indicated at branch points. The tree is drawn to scale 
(scale bar, 0.2 amino acid substitutions per site). Figure and legend adapted from latest report on Virus 
taxonomy by ICTV (Groot, 2011) 
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1.3 CoV Taxonomy 
Order Nidovirales is shared together by families of coronaviruses, Arteriviruses and 
Roniviruses. Family Coronaviridae (a monophyletic cluster in the order Nidovirales) has 
been categorized in to sub-family Coronavirinae and Torovirinae. The sub-family 
Coronavirinae has been variously sieved originally into three groups based on serological 
properties of antigenic cross-reactivities (Lai, 2001).  
The recent viral taxonomic convention (Groot, 2011) establishes CoV species on genetic 
basis in to three approved genera, Alpha-, Beta- and Gamma-CoV with a tentative new 
member, Delta-CoV (Fig 1.1). Demarcations among these genera are based on the rooted 
phylogeny and calculations of pair-wise evolutionary distances for the conserved domains in 
the CoV replicase polyprotein. Currently, complete genomic data are available from around 
300 CoV. Accordingly, high ranking clusters corresponding to genus and sub-family levels 
are recognized. Besides, evidences suggest that both the alpha- and beta-CoV lineages 
originate from the bat gene pool (Woo et al., 2007, Lau et al., 2012, Lau et al., 2010). Typical 
prototypes of each include Transmissible GastroEntritis Virus (TGEV), HCoV-229E, HCoV-
NL63 (genus alpha-CoV); Mouse Hepatitis Virus (MHV), HCoV-OC43, SARS-CoV, 
MERS-CoV (Beta-CoV) and Infectious Bronchitis Virus (IBV) (Gamma-CoV). The new, 
though officially unapproved genera, Delta-CoV has been compiled from findings on CoV in 
bird species (Groot, 2011). 
1.3.1 Genus Alpha 
This genus contains all CoV of the previously classified CoV phylogroup I. Albeit their very 
close phylogenetic relatedness, the CoV in this genus exhibit the presence of a unique 
cleavage product of their replicase polyprotein, nsp1, different in size and sequence from that 
in beta-CoV and absence of similar candidate sequence in gamma-CoV. These CoV also 
exhibit presence of commonly shared accessory gene for dispensable multispanning alpha-
CoV specific membrane protein (αmp) which for some members is the only accessory protein 
and for some like the canine members there can be up to 6 accessory genes (Groot, 2011).  
The alpha-CoV genus is a group of important animal and human viruses subdivided into 
several lineages (Groot, 2011). The alpha-CoV1 lineage comprises two types of canine 
(CCoV and CCoV-NTU336) and feline (FCoV and FIPV) CoV, porcine respiratory virus 
(PRCV) and transmissible gastroenteritis virus (TGEV); another lineage includes human CoV 
hCoV-229E and HCoV-NL63, and other members of the genus alpha are porcine epidemic 
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diarrhea virus (PEDV) and some bat CoV. The animal species victimized by the respectively 
specific alpha-CoV are all mammals. Humans (HCoV-229E and HCoV-NL63), Cats (Feline 
CoV: type I and type II), dogs (Canine CoV: type I and type II), pigs (TGEV, PRCV, PEDV), 
and Bats.  
TGEV is the most extensively studied CoV of the species alpha-CoV1. TGEV affects mainly 
the enteric tract with the onset of severe diarrhea and dehydration but can also trigger Lower 
tract respiratory infections (LTRI), leading to about 90% death toll in newborn piglet 
(Cavanagh, 2005). The attachment of TGEV to sialic acid has also been indicated necessary 
for its enteric tropism (Groot, 2011). PRCV, a distinct homolog with a deletion of the N-
terminal 250 residues of the S glycoprotein exhibits only respiratory tropism suggesting that 
the N-terminal domain is responsible for the TGEV enteric tropism.  
HCoV-229E is the first discovered (around mid-1960s) human CoV and along with HCoV-
OC43 (beta CoV) causes very mild colds in humans or pneumonia in immune-compromised 
patients (McIntosh, 2005). Another closely related alpha-CoV is the HCoV-NL63, which 
uses a distinct entry receptor, as presented below.  
PEDV was first discovered in Europe but had become more problematic in Asian countries 
and now with current rediscoveries from US of a new strain, highly mutated at spike(Wang et 
al., 2014) to which vaccines (developed from previous strain CV777) are partially protective 
(Song and Park, 2012). PEDV causes severe diarrhea and dehydration in piglet. PEDV has a 
tropism distinct from TGEV and it cannot infect ST cells, a cell line highly susceptible to 
TGEV (Nam and Lee, 2010). 
1.3.2 Genus Beta 
This genus comprises CoV with distinct nspI sequence than alpha-CoV and contains four 
distinct lineages (Fig.1.1): A (MHV, HCoV-HKU1 and the beta1-CoV), B (SARS-CoV), C 
(Bt-CoV HKU4, HKU5 and MERS-CoV), and D (Bt-CoV HKU9).The most representative 
prototype CoV of this genus are HCoV-OC43, MHV and SARS-CoV, and the recently 
emerging MERS-CoV. Lineage A CoV harbour an extra short spike like glycoprotein, HE 
(Hemagglutinin Esterase). 
HCoV-OC43 also causes common cold and pneumonia in elderly populations as well as 
severe LTRI in immuno-compromised patients such as those undergoing chemotherapies 
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and/or infected with HIV. It exists as four genotypes: A, B, C and D, wherein D aroused from 
natural recombinations over time (Lau et al., 2011).  
MHV strains have been the best studied beta-CoV before the SARS-CoV emerged especially 
in laboratory mouse both in vitro and in vivo. Certain MHV Strains cause inflammations in 
several mice organs like the neurotropic strains JHM and A59 responsible for acute 
encephalitis and chronic demyelination in survivors, the latter serving as a model to study 
multiple sclerosis. Both innate and adaptive immunity are crucial for host defense towards 
MHV (Bender and Weiss, 2010, Lane and Hosking, 2010).  
SARS-CoV brought corona-virology to center of attention from research communities 
through its global epidemic reporting a fatality rate of 9.6% (2004). The SARS progresses 
with flu like symptoms with fever over 100ºF followed by shortening of breath and 
pneumonia. Long-term effects may include pulmonary fibrosis, osteoporosis, femoral 
necrosis and in some major depressive disorders. It can be more damaging from reactions 
within immune system called „cytokine storm‟(Perlman and Dandekar, 2005).  
MERS-CoV, also called CoV-EMC for first isolate at the Erasmus Medical Center, is a 
human CoV that emerged in Saudi Arabia by 2012 a decade after SARS epidemic. Until May 
2014, MERS has claimed 250 deaths from 700 registered human cases from 20 countries. 
Sharing 90% sequence identities with bat-CoV HKU4 and HKU5, it docks in lineage 2C of 
the beta-CoV. Within the lineage C, initial MERS isolates belonged to clade A cluster 
(EMC/2012 and Jordan N3/2012) and genetically distinct new cases belong to clade B (Chu 
et al., 2014).  
1.3.3 Genus Gamma 
This genus generally lacks the nspI fragment present in alpha and beta-CoV. IBV infects 
chickens and it was the first known CoV from 1930s, which exemplifies highly contagious 
CoV infection in fowls affecting enteric, respiratory, renal, and reproductive systems (Casais 
et al., 2001, Cavanagh, 2007). This brings huge annual losses to poultry farms running on egg 
and meat production (Cavanagh, 2007). Disease progresses by leading to loss of ciliary 
motion in respiratory epithelia, desquamation, mucus deposition, and necrosis. This 
ultimately culminates in respiratory distress followed by viremia to nephrons and tubules in 
the kidneys that become swollen. Its then extends to oviduct where it causes lesions in uterus 
and magnum and thereby hampers egg production. 
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1.4 CoV genome organization 
CoV RNA genome is infectious, nonsegmented, single stranded and like most eukaryotes is 
5‟ capped and 3‟ polyadenylated (Masters, 2006). The RNA genome (Fig 1.2D) starts at the 
5‟end with a leader RNA (L, 60-80 nt) followed by 5‟ (200-600 nt) UTR and then by two 
overlapping ORF, 1a and 1b, which encompass 60% of the genome (approx. 20 kb). These 
encode for polyproteins rep1a and rep1b by means of ribosomal frameshifting (Holmes and 
Lai, 1996), which can be processed proteolytically to nonstructural proteins (Nsps), viral 
RNA dependent RNA polymerase (RdRp), helicase, papain like proteases (PL1
pro
 and 
PL2
pro
), and main protease (M
pro
) to name a few (Groot, 2011). The non-structural genes are 
followed by CoV structural genes invariantly in the order 5‟-SEMN-3‟expressed from a 3'-
coterminal nested set of subgenomic mRNAs (Fig. 1.2D). At least eight accessory genes are 
intercalated among the structural genes, which may be essential for natural infection though 
not in vitro. Finally a 3‟ UTR (200-500 nt) is flanked by a polyadenylation signal. The UTRs 
share genome replication and encapsidation signals with adjacent and internal coding regions.  
1.5 CoV structural proteins 
Spike (S) is a large (17-20 nm, 1128-1427 aa peptide, mol. mass 150-180 kDa) petal shaped, 
type I membrane protein (Fig 1.2A and B) which anchors to host cell membrane receptors, 
induces membrane fusion and is also a major target of CoV neutralizing and 
hemagglutination-inhibiting antibodies (Masters, 2006, Cavanagh, 2005). It exists as a 
homotrimer in mature form with each monomer comprising several structural and functional 
regions. The globular N-terminal S1 region is highly variable among CoV species, mediates 
receptor recognition and is responsible for altered pathogenicity and antigenicity of the CoV 
(Masters, 2006). The membrane proximal stalk, S2, is more conserved and bears two heptad 
repeat regions (Fig 1.2B) with a coiled-coil structure involved in the virus-cell fusion reaction 
during virus entry into cells. The S1 and S2 regions form a single polypeptide that can be 
cleaved by host proteases and extent of cleavage depends on host type and varies among 
CoV. Spike from most CoV of the genus alpha are not cleavable though few as feline 
infectious peritonitis virus (FIPV) can induce cell-cell fusion (Lai, 2006, Masters, 2006).  
Membrane protein (M) is a 218-263 aa long (25-30 kDa), type III glycoprotein with N-
terminal ectodomain composed of either N-linked (IBV, TGEV, SARS-CoV) or O-linked 
(MHV) glycans. It has a long C-terminal endodomain that associates with the inner 
membrane leaflet to form a thick matrix like lattice, explaining the extraordinary thickness of 
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the CoV envelope. Vital roles in virus assembly like packaging genomic RNA into 
nucleocapsid are ascribed to M protein (Lai, 2006, Masters, 2006). 
A 
 
B 
 
C 
 
 
 
D 
 
 
Figure 1.2. General structural and genomic organization in CoV. A. Schematic drawing showing 
morphological features of coronavirus particles and its envelope glycoproteins. B. Detailed scheme of Spike 
glycoprotein with the globular S1 portion and the elongated stem formed by the S2 region. The four 
modules and the antigenic sites C, B, D and A defined in the S1 of TGEV are shown (Reguera et al., 2011). 
The two heptad repeats (HR) of S2 are in rectangles. The N terminus of S1 and the antigenic site A is in 
close contact with S2 (Reguera et al., 2011). C. Electron micrograph of a CoV (the Centers for Disease 
Control and Prevention's Public Health Image Library (PHIL), identification number 4814). D. Genomic 
organization of the CoV prototypes respective to three approved genera of CoV. 
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Envelope protein (E) is a small 77-109 aa (8.4-12 kDa), integral membrane protein that 
forms pentamers and has cation-selective ion channel activity (Wilson et al., 2004). It is 
required in virion assembly and morphogenesis, and is a virulence factor in SARS-CoV. 
Nucleocapsid Protein (N) is a 349-470 aa (50-60kDa), RNA binding phosphoprotein 
responsible for genome encapsidation, RNA synthesis, translation, exhibits RNA chaperone 
activity and act as type I interferon antagonist (Lai, 2006). 
Hemagglutinin Esterase protein (HE) is a short spike-like glycoprotein found only in 
lineage A of the beta-CoV genus and in MHV has been known to interact with sialic acids. 
CoV HE proteins share 30% amino acid sequence similarity with that of influenza C virus. It 
may help initial adsorption of the CoV to the host cell membrane, but it cannot initiate 
infection in the absence of spike protein (Lai, 2006). 
1.6 Immunogenicity of CoV envelope glycoproteins  
The CoV S proves an important target for T cell response and epitopes located in its N-
terminal portion elicit the production of virus-neutralizing antibodies. The S protein, when 
inoculated alone, can induce protective immunity (Cavanagh, 2005). For instance, the S1 
subunit of IBV S protein has been used as an imunogen in various ways, either by direct 
removal from virus using either urea or non-ionic detergent (Cavanagh, 2005) or by 
expression in insect cells following a recombinant baculovirus vector (Song et al., 1998). 
Immunizations with these S1 preparations induced protective immune responses in about 
80% chickens. Greater protection was reported by single oral administration of non-
pathogenic fowl adenovirus expressing S1 subunit (Johnson et al., 2003). Similar protection 
of mice has been seen against lethal challenge with MHV, using its S expressed in adenovirus 
vector or recovered from purified virus (Wesseling et al., 1993, Daniel and Talbot, 1990). N 
terminal epitopes in the CoV M protein also induce neutralizing antibodies that function in 
the presence of the complement system (Woods et al., 1988). The N protein, a dominant 
antigen during infection, like the S, can also induce T cell responses (Boots et al., 1992). The 
HE protein solely found in group A Beta-CoV, also induce antibodies that prevent virion 
binding to O-acetylated sialic acids or inhibit sialate-O-acetylesterase activity. The Spike and 
HE ectodomains are highly variable, indicating vast antigenic drift that may be a result of 
probable RNA recombinations inter and intraspecies. Besides these, both structural and non 
structural proteins prove to be CD4
+
 and CD8
+
 T cell antigens. 
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1.7 Coronavirus infectious cycle 
CoV infection cycle (Fig. 1.3) initiates with host recognition and S binding to the species-
specific host cell membrane receptor. This entails a battery of events that deposit the viral 
nucleocapsid in to the host cell cytoplasm.  
 
 
 
Figure 1.3. Coronavirus infection cycle. Infection initiates with recognition of specific host cell receptor 
(shown APN) by CoV spike (S) protein. Penetration and uncoating of CoV occurs following S mediated 
fusion of the viral envelope with host cell plasma membrane. Gene 1 of CoV genomic RNA translates into a 
polyprotein in turn processed to yield Pol proteins comprising the transcription-replicase complex. These use 
genomic RNA template to produce negative-stranded RNA, which in turn are synthesized into full length 
genomic RNA and subgenomic RNA. Each mRNA is translated to only the protein encoded by 5‟-most open 
reading frame (ORF). These include structural proteins N, M, E, S and HE (shown as in Fig 1.2A) and 
several nonstructural proteins. The N protein and newly synthesized genomic RNA assemble in to helical 
nucleocapsids. All the structural proteins then assemble at the ER and prepare for CoV budding at the 
endoplasmic reticulum-golgi intermediate complex (ERGIC). The S and HE proteins are glycosylated, 
trimerized, and carried to golgi apparatus and along with M are incorporated to the maturing virions, which 
are released by exocytosis-like fusion of smooth walled vesicles with the plasma membrane  
 
Enveloped viruses utilize a fusion process to penetrate the host cell membrane. The entry of 
CoV into the cell cytoplasm is preceded by the fusion of virus and host cell membranes 
following different pathways. Some CoV fuse directly with the cell membrane at neutral pH, 
as has been shown in some strains of MHV. Other CoV, such as TGEV (Hansen et al., 1998), 
SARS-CoV (Hofmann et al., 2004, Simmons et al., 2004, Yang et al., 2004) and HCoV-299E 
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(Nomura et al., 2004) require a low pH step for cell entry, and fusion occurs in endosomes 
after endocytosis of receptor-bound viruses. Following penetration into the host cell, the first 
Open Reading Frame of the positive stranded RNA genome translates into a huge 
polyprotein, which is proteolytically processed into a collection of Pol proteins that 
contribute to the a transcription-replicase complex (Fig. 1.3). Pol then uses a negative strand 
RNA intermediate to synthesize both new copies of complete genome and sub-genomic 
mRNA species. The latter are translated into structural and accessory proteins. The structural 
proteins are pinned into the endoplasmic reticulum (ER) wherefrom they tread to the 
endoplasmic reticulum-golgi intermediate compartment (ERGIC). N proteins encapsidate the 
progeny genomes to form the nucleocapsid, which assembles with the membrane bound 
components to form virions by budding through the ERGIC (Fig. 1.3). Excess of S and HE 
proteins skip incorporation into virions and are transported to the plasma membrane, where 
they assist cell-cell fusion or hemadsorption, respectively The last step culminates into export 
of virions to the plasma membrane in smooth walled vesicles and its release through 
exocytosis (Masters, 2006, Lai, 2006). 
1.8 Factors affecting CoV cell entry 
1.8.1 Membrane fusion 
The CoV S is a class I viral fusion protein functionally similar to that of phylogenetically 
distant RNA viruses such as HIV, influenza and Ebola Virus (Bosch et al., 2003). Like the 
class I fusion proteins, the S2 region adopts a helical structure, and it harbours a fusion 
peptide upstream of a heptad repeat 1 (HR1) and a transmembrane domain downstream of 
HR2 (Fig. 1.4). As in other enveloped viruses, the initiation of the fusion reaction requires 
partial disassembly of the trimeric spikes and the exposure of the fusion peptide for binding 
to the host cell membrane.  In the follow up, the two HR form a six helix bundle, a highly 
stable oligomer with 1.45 nm rod like structure (Bosch et al., 2003) . This bundle brings viral 
and cell membranes in close proximity and facilitates its fusion (Fig. 1.4).  
In some CoV, anchoring of the S to its specific host cell receptor triggers a major 
conformational change in the S that triggers fusion. Other CoV, such as TGEV and SARS-
CoV, fusion requires an acidic pH step. This difference in pH requirement is reflected in 
distinct modes of CoV cell entry (Masters, 2006). Some MHV strains fuse at the plasma 
membrane, while others enter via receptor-mediated endocytosis and fusion in the acidified 
endosomes. In MHV, the switch between these two cell entry modes have been ascribed to 
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residues in HR region of S2, while SARS-CoV could strictly revert to direct cell surface 
fusion in cells pretreated with protease at the earliest stages of infection. Receptor induced 
conformational changes in CoV S have been studied mostly in MHV (Masters, 2006). Highly 
virulent strain MHV4 (JHM) carries S in a metastable conformations with high fusogenic 
potential; it can mediate fusion among infected cells lacking the receptor (Gallagher and 
Buchmeier, 2001, Krueger et al., 2001, Nash and Buchmeier, 1996). 
 
 
 
Figure 1.4. CoV-host cell membrane fusion. Steps of S protein conformational changes that may occur 
during membrane fusion. In the first step, receptor binding, pH reduction and/or (in case of MHV) S protein 
proteolysis induces dissociation of S1 from S. In the second step, the fusion peptide (FP) is intercalated into 
the host cell membrane (the fusion-intermediate stage). In the third stage, the part of the S protein nearest to 
the virus membrane refolds onto a heptad repeat 1 (HR1) core to form the six-helix bundle, which is the final 
post-fusion configuration of the S2 protein. Figure modified from a published source (Heald-Sargent and 
Gallagher, 2012) 
 
The S protein in some CoV is cleaved into S1 and S2 to facilitate exposure of the fusion 
peptide at the N terminus of S2 region toward the cell membrane, but this not an absolute 
requirement for cell fusion in other CoV (Gallagher and Buchmeier, 2001, Keck et al., 1988, 
Yoo et al., 1991). Receptor-binding can mediate undefined changes in the S trimmers that 
initiate the fusion reaction. This has been explored extensively in MHV (Zelus et al., 2003). 
Cholesterol has been shown to influence differently in CoV that fuse on the cell surface or 
after endocytosis. Cholesterol supplementation enhances fusion, while its depletion inhibits 
entry (Thorp and Gallagher, 2004). This effect is not due to clustering of receptors into lipid 
rafts (Thorp and Gallagher, 2004, Choi et al., 2005). However cell-bound virions do cluster in 
14 
 
lipid rafts, indicating another factor that can be important for MHV fusion (Choi et al., 2005). 
HCoV-229E virions bound to its receptor redistributes from disperse pattern to clusters in 
caveolin-1-rich lipid rafts (Nomura et al., 2004). 
1.8.2 Protease requirement  
All alpha-CoV species have spike uncleaved after receptor binding. MHV spike does not 
need proteolytic cleavage for fusion (Stauber et al., 1993), but it seems more efficient in 
cleaved S. Protease treatment of SARS-CoV may render its entry into host cells directly on 
the cell surface without endocytosis (Matsuyama et al., 2005). S proteolysis can thus be 
required to allow membrane fusion among CoV and target host. For instance, TMPRSS2 
colocalizing with the SARS-CoV receptor, cleaves the S and enhances viral entry (Glowacka 
et al., 2011). Despite the utilization of same receptor, HCoV-NL63 and SARS-CoV display 
distinct tropism and pathogenesis (Weiss and Navas-Martin, 2005 ). The lack of function of 
this protease for HCoV-NL63 entry explains partly the lower infectivity of this virus 
compared to the SARS-CoV (Krempl and Herrler, 2001). Cathepsin L, a protease that is 
active in low pH conditions, has been shown to activate HCoV- 229E spike-dependent 
fusion, leading to a cell entry mechanism similar to the SARS-CoV 
Protease requirement may differ between cell-cell and virus-cell fusion. The former correlates 
with the extent and kinetics of S protein cleavage and can be enhanced by trypsin treatment 
(Frana et al., 1985). Cleavage varies among different cells indicating the implication of a host 
protease (Frana et al., 1985). MHV A59 isolate from persistently infected glial cells has 
altered cleavage site, containing RRADR instead of original RRAHR sequence, which 
implies a lag in cell-cell fusion infection spread in infected cells (Gombold et al., 1993). But 
studies with hepatocytes show that viral-cell membrane fusion was not inhibited, indicating 
that cleavage was not a requirement for this process. Role of furin or furin like protease has 
been established based on effect of their inhibitors on in vitro infection, which blocked both S 
protein cleavage and cell-cell fusion but not viral-cell fusion (de Haan et al., 2004). A 
cysteine rich region in the MHV spike operates in cell-cell fusion, mutation of which 
abrogates syncytia formation (Bos et al., 1995).  
1.8.3 pH optima for fusion 
Virus-cell fusion occur at neutral pH in some CoV, which indicates that such events can 
occur directly on cell surface, while other CoV variants require low pH and receptor 
mediated endocytosis. Use of lysosomotropic agents (ammonium chloride, chloroquine, 
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bafilomycin, dansylcadaverine) that neutralize acidic pH environments in endosomal 
compartments, uncovered that some MHV variants fuse in endosomes; other MVH strains 
can fuse at a neutral pH of 7.4 on the cell surface (Kooi et al., 1991, Weismiller et al., 1990). 
More recent studies with the MHV strain A59 have used confocal and electron microscopy 
besides lysosomotropic agents, as well as inhibitors of clathrin-dependent endocytosis (Eifart 
et al., 2007) and a novel β-galactosidase complementation assay. These studies show MHV 
enter by receptor mediated endocytosis (Burkard et al., 2014). The Beaudette strain of IBV, a 
gamma-CoV, shows 90% reduced productive infectivity with ammonium chloride treatment, 
indicating that fusion occurs soon after endocytosis and it is triggered by low pH. Entry could 
be strain specific, as no effect was seen with different IBV strains, indicating probable cell 
surface fusion (Li and Cavanagh, 1992).  
1.9 Cross-species CoV transmission:  
Pathogenicity of the CoV is considered species-dependent as is infection severity; infections 
usually occur on closely related natural hosts. This notion has been challenge by the recent 
CoV outbreaks caused by the SARS- and MERS-CoV. Epidemiologists believe that SARS 
virus originated in bats (natural reservoir hosts), which was transmitted to Himalayan palm 
civets, Chinese ferret badgers, and raccoon dogs (amplification and transmission hosts) and 
subsequently introduced into humans due to handling or consumption of these game animals 
in the Guangdong province of China. Similar bat to human spread has been accounted for 
HCoV-229E; cattle to human in case of HCoV-OC43 and cattle to dogs in Canine respiratory 
CoV (McIntosh et al., 1970, McIntosh et al., 1967).  
Alarmed with the SARS event of 2003, molecular epidemiology surveyed two more human 
CoV, HCoV-HKU1 and HCoV-NL63, both causing common cold with latter leading to 
bronchitis in children (Woo et al., 2005). More studies revealed a new lineage of solely avian 
species (Thrush, Bulbul, and Munia-CoV) with relatives in Asian leopard, Chinese ferret 
badger (all mammals). This supports a new notion that bat coronaviruses serve as a reservoir 
of alpha-CoV and beta-CoV, while gamma-CoV and delta-CoV originate from birds (Patrick 
C. Y. Woo, 2012). However these hypotheses may still need a broader animal CoV sampling 
(Groot, 2011). 
The emerging MERS-CoV is distinct from other endemic human CoV (HCoV-OC43 and 
HKU1) with a uniquely strong tropism towards non-ciliated (while most respiratory CoV 
target ciliated) bronchial epithelia, where it evades innate immunity and antagonizes IFN 
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production. Its human to human transmission requires a higher respiratory inoculum, as the 
virus doesn‟t infect more than 20% respiratory epithelia, so only people in close contact with 
the infected individual are prone to transmission (OMRAN, 2014). Though, until recently 
researchers revealed that the human to human transmission mode has been suspended by the 
virus, it could prove a silence before the storms as 20% of the individuals asymptomatic for 
infection still exhibited MERS-CoV antibodies in their blood. Preliminary isolate from 
Egyptian Tomb Bat genetically matched perfect with the index patient. Later, other CoV 
isolates from bat species (Nycteris in Ghana and Pipistrellus bats in Europe) were diagnosed 
to occupy 2C lineage among beta-CoV and were phylogenetically very related to MERS-
CoV (Augustina Annan, 2013). This indicated that bats could be a natural reservoir of the 
MERS-CoV as in the case of SARS-CoV. However, latest reports from the Journal of 
Emerging Infectious Diseases, advocate camels (Chu et al., 2014) to be the natural niche, 
with 99.9% genetic match to human clade B MERS-CoV. It must have been transmitted to 
humans by either close contact with camels or drinking camels‟ milk. Supportive reports 
evidence 50% Omani and 14% Spanish camels have spike specific antibodies to MERS-CoV 
(Reusken et al., 2013) and they might have spread to different countries during imports. More 
recent studies document around 90% of Saudi Arabian camels positive for MERS-CoV, 
suggesting camels as the primary source animal for MERS-CoV, bats rather as ultimate 
reservoirs. These reports also confirm instances of direct camel to human transmissions of 
MERS-CoV (Memish et al., 2014a, Memish et al., 2014b). More recently, it came to news-
boards that the MERS-CoV could be air borne: a research conducted by Abdulaziz University 
(Jeddah) on the air samples collected from the camel barns in Saudi Arabia. 
Recurrently, CoV infections can cross species barrier and they originate from bats. The 
question is, why bats? There are globally 60 viral species associated with bats and 
surprisingly 59 of these are RNA viruses that can potentiate emerging and remerging cases of 
human infection. Bats (approx. 930 species) belong to the second largest order within the 
mammalian class (approx. 4600 species) after rodents (2000 species) and so cover 20% of the 
mammalian dynasty (Samson Wong, 2007). They are geographically ubiquitous (except poles 
and oceanic islands), with diverse diets (plants, insects, animals and a blood diet), and wide 
colonization range (10 to 200,000 individuals per colony). It is interesting how bats could 
harbor such huge diversity of CoV (and other infectious agents) and so lend a big hand in 
viral ecology and evolution and act as natural wildlife reservoirs for these viruses.  
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1.10 Coronaviruses receptors 
Spike proteins are the primary receptor binding proteins on in the CoV, which specifically 
target a variety of cell surface molecules (Table 1.1) for entry into host cells. This interaction 
remains principal if not the only, determinant for CoV tissue tropism and host range (Masters, 
2006). Non-permissive cells can become permissive to a CoV by the expression of the host 
receptor (Delmas et al., 1992). Swapping of spike among different CoV changes the host cell 
specificity, as it has been shown with FIPV and MHV (Kuo et al., 2000, Haijema et al., 
2003); and among the distinct TGEV (Sanchez et al., 1999) and MHV strain (Navas et al., 
2001, Phillips et al., 1999). In addition, the remarkable cross-species transmission potential of 
certain CoV is related to virus adaptation to the use of orthologous receptor molecules by 
subtle modification in their spike glycoproteins. 
The S1 region of the spike is largely variable in sequence and length among CoV, and is 
specialized in recognition of cell surface receptors (Li, 2012, Masters, 2006). Receptor-
binding domains (RBD) can be located at the N- and/or C-terminal moieties of the S1 region 
(Li, 2012, Peng et al., 2011). The S glycoprotein N-terminal domain (NTD) can function as a 
RBD; it can be the only S1 domain engaged in receptor recognition, or in conjunction with C-
terminal RBD, can broaden tissue tropism of certain CoV. The NTD region adopts a galectin-
like structure and it appears as a domain acquired from the host during evolution of CoV (Li, 
2012, Peng et al., 2011). In most CoV, the major determinants of cell tropism are found in the 
C-terminal portion of the S1 region (Masters, 2006). These RBD can usually fold 
independently and adopt unique structures in CoV, so that they can be considered genuine 
CoV RBD (Peng et al., 2011, Li et al., 2005a, Wu et al., 2009, Chen et al., 2013). The CoV 
can use distinct entry receptor molecules, responsible for their broad host range and tissue 
tropism; however, they preferentially recognize ectoenzymes. The reason of this specificity is 
currently unknown. 
Aminopeptidase N (APN) was the first alpha-CoV1 entry receptor described. It serves as 
receptor for CoV, like TGEV, PRCV, PEDV, FeCoV, FIPV, CCoV, and HCoV-229E over 
respiratory and enteric epithelia (Table 1.1). The APN RBD locates in the C-terminal portion 
of the S1 region. APN is type II membrane protein that forms dimers on the cell surface (see 
below). Other metalloproteases besides APN can also serve as CoV entry receptors. 
Angiotensin converting enzyme 2 (ACE2) is a zinc-carboxypeptidase involved in cardiac 
functions and acts as a receptor for SARS-CoV and HCoV-NL63. Both CoV bind similar 
receptor regions despite their structurally distinct RBD (Li et al., 2005a, Wu et al., 2009). 
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Catalytically inactive mutants for ACE2 do not exhibit any defect in SARS-CoV spike 
binding (Moore et al., 2004) or spike mediated syncytia formation (Li et al., 2003). The 
viruses recognize a single domain of the ACE2 protein and they do not bind to the catalytic 
site. Recently, a distinct ectoenzyme, dipeptidyl peptidase 4 (DPP4), was identified as the 
entry receptor of the MERS-CoV (Lu et al., 2013, Wang et al., 2013). DPP4, also called 
„adenosine deaminase complexing protein 2‟ or CD26, is an exopeptidase that cleaves X-
proline dipeptides from the N-terminus of polypeptides. 
It serves as an antigenic enzyme engaged in signal transduction, apoptosis, and immune 
regulation and also works as a tumor suppressor (Pro and Dang, 2004, Havre et al., 2008). Its 
substrate peptides are growth factors, chemokines, neuropeptides, and vasoactive peptides 
(Chen, 2006). Similarly to APN, DPP4 is a type II membrane protein and forms non-covalent 
dimers on the cell surface. It is composed of two domains and MERS-CoV binds to a single 
domain that is distant from the cell membrane (Lu et al., 2013, Wang et al., 2013). 
Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), a424 aa glycoprotein of 
the immunoglobulin (Ig) superfamily, is used as entry receptor by MHV (Table 1.1). 
CEACAM 2 is also envisaged a weak receptor in vitro but not an alternate receptor in vivo. It 
is not a peptidase; MHV uses the spike NTD for binding to the N-terminal Ig-like domain of 
CEACAM1 (Lewicki and Gallagher, 2002, Tan et al., 2002). NTD of other CoV are also in 
recognition of cell surface sialic acids, which can be used as attachment factors or entry 
receptor molecules. TGEV NTD interact with an unknown mucin-like glycoprotein that 
contains sialic acid on the porcine intestinal brush border epithelia, responsible of its 
enterotropism (Krempl and Herrler, 2001, Schwegmann-Wessels et al., 2002). N-acetyl-9-O-
neuraminic acid (Neu5,9Ac2) was found as an entry receptor for BCoV (Schultze and 
Herrler, 1992, Schultze et al., 1991b, Schultze et al., 1991a). Sialic acid residue α2,3- linked 
N- acetyl neuraminic acid is also involved in hemagglutination of RBC during IBV infection 
(Schultze et al., 1992, Winter et al., 2006). Spike-linked carbohydrates can be also used by 
CoV to attach to host cells. The SARS-CoV can bind to the lectin CD209L (also called 
LSIGN or DCSIGNR), although it is less efficient SARS-CoV receptor (Jeffers et al., 2004, 
Marzi et al., 2004, Yang et al., 2004). 
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CoVGenus Species Receptor 
Alpha • Alphacoronavirus 1 comprising:  
      Feline Coronavirus (FCoV) serotype 2 Aminopeptidase N 
      Canine Coronavirus (CCoV) serotype 2 Aminopeptidase N 
      Transmissible gastroenteritis virus (TGEV) Aminopeptidase N/Sialic acid 
• Human coronavirus 229E Aminopeptidase N 
• Human coronavirus NL63 ACE2 
• Porcine Epidemic Diarrhea Coronavirus (PEDV) Aminopeptidase N 
• Rhinolophus bat coronavirus HKU2  
• Scotophilus bat coronavirus 512/05 
• Miniopterus bat coronavirus 1 
• Miniopterus bat coronavirus HKU8 
Beta • Betacoronavirus 1 comprising:  
      Bovine coronavirus (BCoV) Neu 5,9 Ac2 
      Human coronavirus OC43 (HCoV-OC43) Neu 5,9 Ac2 
      Equine coronavirus (ECoV)  
     Human enteric coronavirus (HECoV) 
     Porcine haemagglutinating encephalomyelitis virus (PHEV) 
     Canine respiratory coronavirus (CrCoV) 
• Murine coronavirus comprising:  
      Existing species of mouse hepatitis virus (MHV) CEACAM1 
     Rat coronavirus 
     Puffinosis virus 
• Human coronavirus HKU9 
• Rousettus bat coronavirus HKU4 
• Tylonycteris bat coronvirus HKU5 
* MERS-CoV  DPP4 
• SARSr-CoV (SARS related Coronavirus) comprising  
      Human SARS-CoV ACE2 
     Rhinolophus bat viruses 
Gamma • Avian coronavirus comprising: Sialic acid 
 IBV, Various coronaviruses infecting turkey, pheasant, duck, 
goose and pigeon 
• Beluga Whale coronavirus SW1 
Delta • Bulbul coronavirus HKU11  
• Thrush coronavirus HKU12 
• Munia coronavirus HKU13 
Table 1.1 Coronavirus genera, host and receptors. Table adapted from a published report (Belouzard et al., 
2012) and modified by including MERS-CoV. Typical representatives have been highlighted in red. 
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1.11 Aminopeptidases N  
APN (EC3.4.11.2) is 150-160 kDa, type II membrane metallopeptidase that belongs to the 
M1 family (Look et al., 1989, Luan and Xu, 2007). Also called CD13, it is a multifunctional 
protein winning the title of moonlighting enzyme. Many of its features were unveiled after its 
crosslinking with monoclonal antibodies, overexpression or silencing in variety of cell lines, 
gene-knockouts in animal models and/or by use of catalytic inhibitors. Many of these features 
are very well documented, though most still seek further studies (Mina-Osorio, 2008).  
1.11.1 Structural features 
APN coordinates a zinc ion at its active site through highly conserved consensus HEXXH 
and GXMEN motifs (Hooper, 1994) which are critical for APN‟s catalytic activity (Noren O, 
1997, Look et al., 1989). APN exists as a heavily glycosylated (30% mol. mass) (Danielsen et 
al., 1982, Riemann et al., 1999) head-to-head homodimer on the cell surfaces, and the 
ectodomain protrudes about 10.5 nm from the cell membrane. Compared to other members of 
the M1 family, which usually are monomers, APN are dimers that hydrolyze broad range of 
peptides. Dimerization imparts stability to the APN as it stands harsh environments than the 
intracellular proteins. It may also exist in small proportions as functionally active soluble 
isoform. APN are ubiquitously found over membranes of the microvilla in small intestine, 
renal, intestinal, pulmonary epithelia and also on granulocytes, monocytes, fibroblasts, 
endothelial cells, pericytes of blood-brain barrier and synaptic membranes of the CNS 
(Delmas et al., 1994, Look et al., 1989, Olsen et al., 1988). 
1.11.2 Catalytic functions 
CD13 catalyses the removal of N-terminal amino acids from unsubstituted oligopeptides, 
amide or arylamide, with the exception of peptides with proline in the penultimate position. It 
prefers neutral amino acids and the order of preference for substrates is 
Ala>Phe>Tyr>Leu>Arg>Thr>Trp>Lys>Ser>Asp>His>Val. Its peptidase function cleaves 
individual amino acids in the intestinal lumen, peptides involved in MHC binding and also 
helps degradation of neurotransmitters at the synaptic junctions (Larsen et al., 1996, Matsas 
et al., 1985, Noren O, 1997). Distinct open and closed conformational states have been 
observed among the M1 family members and these movements are thought important for 
peptide catalysis (Kochan et al., 2011). 
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1.11.3 Receptor functions 
APN acts as a receptor for most alpha-CoV1 subgenus, such as porcine (TGEV, PRCV, 
PEDV), feline (FIPV and FeCoV), canine (CCoV) and HCoV-229E. Feline APN can serve as 
a receptor for all APN receptive CoV, thus indicating cats being the origin of host‟s 
specificity in alpha-CoV, which has been related to different glycosylation pattern of CD13 
among hosts (Tresnan and Holmes, 1998, Hegyi and Kolb, 1998). Accordingly, the host 
range of CoV primarily associates with receptor usage, while the disease type does not. CoV-
receptor and APN enzymatic functions are considered independent. This has been indicated 
by the use of catalytic inhibitors of APN, which failed to influence CoV infectivity in vitro 
(Delmas et al., 1994, Moore et al., 2004).  
1.11.4 Other moonlighting functions of APN 
Ligand-binding to APN may results in its internalization, as seen with antibodies that mask 
its surface activities (Mina-Osorio et al., 2006). Many molecules or auxillary proteins viz., 
galectin 3, galecin 4, RECK, and tumor associated antigen L6, regulate APN cellular 
trafficking in order to either control its optimal functions or its cell signaling capacities 
independent to its receptor functions. Praising its roles in MAPK phosphorylation, calcium 
influxing, and cell adhesion, APN has been grouped into the list of signal regulators (SR). 
Besides, catalytic activity of both soluble and surface APN forms are correlated with 
invasiveness of various tumor cells, thus qualifying them as important indicators of many 
neoplastic disorders, including those of skin, colon, kidney, lung, stomach, bone and prostrate 
tumors (Kehlen et al., 2003, Fujii et al., 1995). APN is a target for cancer chemotherapies; 
drugs that bind this protein have been studied for treating tumors, some of which are 
in clinical trials. APN is also involved in cell differentiation as evidenced from their altered 
expression in different cell lines which potentiates its use as a diagnostic marker for peculiar 
lymphoma and leukemic disorders (Nakase et al., 1996). This function is also correlated with 
catalysis possibly because of its processing of peptides that mediate the induction or secretion 
of growth factor involved in differentiation (Lohn et al., 1997). More recent interest has been 
envisaged on their role in stem cell differentiation (Chen et al., 2007). Other important 
functions that APN plays in cell biology relate to cell proliferation, programmed cell death, 
motility of tumor cells and spermatozoids, chemotaxis, antigen presentation, cholesterol 
crystallization and uptake, phagocytosis, angiogenesis and cell adhesion, and they have been 
faithfully considered with demanding details in recent literature (Mina-Osorio, 2008). 
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2.0 OBJECTIVES 
 
The following objectives were realized during the course of study: 
2.1 Expression and purification of the human and pig APN ectodomains 
and CoV S length variants.  
 
2.2 Expression and purification of the CoV S length variants. 
 
2.3 Determination of APN ectodomain structures. 
 
2.4 Crystal structure of an alpha-CoV RBD bound to its APN receptor. 
 
2.5 Identification of critical virus-receptor binding motifs in the TGEV-
APN interface. 
 
2.6 Influence of the APN conformation and peptidase activity in CoV 
binding and infection. 
 
2.7 Characterization of the main antigenic site in the spike of TGEV. 
 
 
 
  
 
 
 
 
CHAPTER 3 
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3. MATERIALS AND METHODS 
3.1 Cells and media 
Bacterial cell Top10F‟ and DH10B cultures of E.Coli were used for competent cell 
preparation for routine gene cloning procedures, maintenance of plasmid and BACmid 
vectors respectively. LB media supplemented with appropriate antibiotic was used for 
bacterial cultures. Mammalian cells HEK293T cells were used in transient transfections to 
test soluble and surface expressions of glycoproteins. CHOLec 3.2.8.1 (CHOLec) cells were 
used to generate clones stably expressing recombinant soluble proteins intended for 
crystallization (Stanley, 1989, Casasnovas and Springer, 1995, Ordono et al., 2006). BHK21 
and CHOK1cells were used in stable surface expression of proteins intended for carrying out 
protein interaction assays and were also accompanied by ST cells in virus infection 
experiments. Eagle‟s Minimum Essential Medium (E-MEM) supplemented with non-
essential amino acids, sodium pyruvate, glutamic acid, asparagines and nucleoside (Sel-
MEM), as well as 10% heat inactivated FCS was used as growth and maintenance media for 
tissue monolayer culture of adherent CHOLec and CHOK1 cells. For selection of their stable 
transfected CHO cell clones 25-30µM of L-methionine sulfoximine (MSX) selective drug 
was used in Sel-MEM supplemented with 5-10% dialyzed FCS. Dulbecco‟s Modified Eagle‟s 
Medium (DMEM) culture media supplemented with 10% heat inactivated FCS was used for 
adherent 293T, BHK and ST cells. For serum free 293T expression, transfectants were 
cultured in either serum free DMEM or OptiMEM-I medium (Life Technologies). 
Mammalian cell culture media was also supplemented with antibiotics, a 
penicillin/streptomycin mixture or gentamycin, in order to avoid bacterial contamination. 
Geneticin (G418) antibiotic was used to sort stable BHK-21 cell transfectants. 
3.2 Protein Sequences 
Accession numbers used for pig APN and human APN are P15145 and M22324, 
respectively. TGEV spike is Q0PKZ5. PRCV HOL87 S protein sequence is reported in 
published literature (Sanchez et al., 1992). 
3.3 Recombinant protein expression and purification 
 Positional cloning was routinely performed using polymerase chain reaction (PCR) and gene 
specific sets of primers designed to anneal and amplify genes encoding protein of interest 
from full length cDNA templates. Restriction enzyme recognition sites were also designed to 
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flank the amplicons. These restriction sites were used to transfer cDNA among different 
expression vectors. Constructs intended for expression of soluble ectodomains, required a 
signal peptide for extracellular secretion. This was facilitated by cloning the cDNA 
amplicons into a pDisplay (Invitrogen) derived vector, pBSKS-D (Fig. 3.1A) which imparts a 
human IgK leader signal sequence followed by a Hemagglutinin A (HA) tag.  
A 
 
 
 
B 
 
 C 
 
 
 
 
Figure 3.1. Mammalian expression vectors. A. pBSKS-D cloning vector derived from pDisplay by 
introducing its human IgK (huIgK) secretory signal and Hemagglutinin A (HA) epitope tag engineered into 
pBSKS+ plasmid (Stratagene).B. pEF vector derivatives of pEF-BOS (Mizushima and Nagata, 1990) 
containing SV40 origin of replication, human EF-1a promoter , polyadenylation site (polyA), regions of 
LacZ’, M13, and ampicillin resistance. C-terminal Tag (highlighted in red) included either human IgGFc 
(HuIgG Fc), HA or FLAG tag. C. pBJ5GS vector with Glutamate synthetase (GS) gene for selection of stably 
expressing CHO cell clone under glutamine starvation. Cloning SalI-NotI fragment from recombinant pEF-
vector (in B) in to XhoI-NotI sites of pBJ5GS dissolves SalI and XhoI sites in pBJ5GS. Routinely used 
restriction enzymes within the Multiple Cloning Sites (MCS) are highlighted in bold. All vectors use 
ampicillin resistance (AmpR) for bacterial selection. 
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Further, cloning involved transfer of SalI-BamHI fragment from recombinant pDisplay to 
different derivatives (Fig. 3.1B) of the vector pEF-BOS (Mizushima and Nagata, 1990). This 
introduced desired C-terminal tags for preparing fusion proteins which aided their antibody-
affinity based purification. A thrombin recognition sequence was also introduced between the 
protein and the C-terminal tags. The recombinant pEF vectors were transfected into 293T 
cells using the calcium phosphate method for transient protein expression (Jordan et al., 
1996). The presence of the proteins in the cell supernatants was monitored by ELISA at about 
3 days post-transfection. 
cDNAs with the required terminal tags were excised from respective recombinant pEF 
derivatives using SalI-NotI restriction site and were cloned into the unique XhoI-NotI site of 
the pBJ5-GS vector (Fig. 3.1C). Recombinant pBJ5GS vector were used for preparation of 
stable CHO-Lec clones following the glutamine synthetase expression system (Casasnovas 
and Springer, 1995, Ordono et al., 2006). Clones growing at 30 M MSX and secreting the 
protein to the cell supernatants were selected by ELISA. Cells were subcloned by limiting 
dilution for selection of clones expressing high amount of proteins. Cell clones were grown in 
sterile plastic roller bottles (Greiner bio-one) for large scale protein production.  
All the recombinant glycoproteins used in the study (Fig 3.2) were developed employing the 
above cloning and expression strategy. From a cDNA template encoding full length pig 
Aminopeptidase N (pAPN), specific fragments were PCR amplified using primers APN-N4 
and APN-C2 (Table B, appendix) for the soluble ectodomain and primers APN-N3 and APN-
Call for the surface expressible variant. Primers APN-N4 and hAPN-C1 were used for 
amplifying human APN (hAPN) ectodomain from a full length cDNA template (Look et al., 
1989). Preparation of CoV spike length variants was based on the established modules in the 
S1 globular region and their studied interaction with receptor, pAPN (Reguera et al., 2011). 
Accordingly, CoV S length variants (Fig 3.2B) were produced using a cDNA template 
encoding full length spike (S) from TGEV (PUR46MAD) and PRCV (strain HOL87). TGEV 
S length variants, S1 (primer Cos-N1 and Cos-C1) and S3 (primer Cos-N1 and Cos-C3) 
included the RBD region which was also exclusively developed (primer Cos-N4 and Cos-
C32). Similarly, generation of PRCV-SH1 used primers Cos-N1 and Cos-C1 while SH3 used 
primers Cos-N1 and Cos-C3 (Table B, appendix). Soluble APN ectodomains and TGEV S 
RBD harbored an N-terminal IgK leader followed by an HA tag (Fig 3.2A and B). At the C-
terminus, soluble pAPN ectodomain was flanked by a Flag tag, while its surface expressible 
construct carried an HA tag. For secretion in cell supernatants, S1, S3 (TGEV S), SH1 and 
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SH3 (PRCV S) harbored endogenous signal peptide at the N terminus, while in case of APN 
and TGEV S RBD, this was facilitated by the human IgK leader sequence during cloning in 
pBSKS-D vector (Fig 3.1A). The S1, S3, SH1, and SH3 glycoproteins carried at their C-
terminal either a Flag or HA tag. The RBD variant carried either a Flag tag (monovalent) or a 
human IgG-Fc protein (divalent) tag at the C-terminus. 
A 
 
B 
 
 
Figure 3.2. Schematic of designed genetic elements for expressing and purifying soluble proteins. A. 
Cartoons depict modular organization of full length APN (top) and modified soluble ectodomains from pAPN 
and hAPN (bottom). The N-terminal cytoplasmic (CYT) and transmembrane (TM) domains in APN were 
substituted by a signal peptide (SP) and an HA epitope. Colored boxes indicate domains I-IV with a white box 
(marked L) corresponding to a flexible polypeptide. Black triangles indicate of N-linked glycosylation sites. B. 
Cartoon (top) depicts general full length CoV spike with N-terminal S1 and C-terminal S2 stalk region (drawn 
smaller in size w.r.t S1 to fit the scope, marked by diagonal bars) followed by TM and CYT domains. Dotted 
vertical lines emphasize S1 region used to construct the length variants (black bars) S1, S3 and RBD from 
TGEV (PUR46MAD) S protein; SH1 and SH3 from PRCV (HOL87) S protein. Antigenic modules C, B, D, 
and A and antigenic sites shown for S1 in both CoV. Blue rectangles locate the receptor binding domain (RBD) 
on respective constructs. 
 
Proteins secreted to culture supernatants were initially purified by affinity chromatography 
using monoclonal antibody against the epitopes either on protein of interest or the tagged 
proteins. For the APN this used 12AC5 mAb against the HA tag and for the CoV spike length 
variants, mAb 6AC3 was used which recognizes epitopes in the antigenic site A (Fig 3.2B). 
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These mAbs were coupled to CL4B-sepharose and packed on to gravity flow glass columns 
(Glass Econo-Column®, BIORAD) equilibrated in a buffer solution (10 mM Tris, 150 mM 
NaCl, pH 7.3). Cell supernatants (1-2 L) were passed through this column followed by 10 
column volumes of wash buffer (10 mM Tris, 150 mM NaCl, pH 8.3). Proteins of interests 
were then recovered as fractions using an elution buffer contacting 20-40 mM glycine (pH 
3.0 for 12AC5 and pH 2.8 for 6AC3 column). Protein elution was immediately followed by 
pH neutralization of the samples (using 1 mM Tris, pH8.0). Column was washed again 
followed by re-equilibration (10 mM Tris, 150 mM NaCl, pH 7.3). Following visualization 
on SDS-PAGE, apparently pure protein fractions were concentrated and further purified by 
size exclusion chromatography in HEPES-saline buffer (20 mM HEPES, 150 mM NaCl, pH 
7.5) and were again analyzed on SDS-PAGE gels. For size exclusion chromatography, 
sepharose columns (GE healthcare) fitted with the Akta-Purifier (GE heathcare) system. 
3.4 Site directed mutagenesis (SDM) 
SDM was performed to introduce point mutations in gene of interest contained in plasmids 
used as template and primers designed (Table B, Appendix). Quickchange kit (Stratagene) 
protocol was followed using either pfuI Turbo (Agilent Technologies) or NzyDNAchange 
(NzyTech) polymerase. Briefly, PCR was performed as recommended and an aliquot was 
checked by electrophoresis to confirm amplification; DpnI treatment was done for 2 hours at 
37
o
C to eliminate template plasmid and amplified plasmid was transformed to Top10F´ 
competent cells. Transformed colonies were selected and plasmid DNA was prepared using a 
kit protocol (Qiagen) to verify the presence of intended mutagenesis by sequencing. 
3.5 ELISA 
ELISA was used as a binding assay for soluble proteins and was performed in 96 well plates 
(Nunc-immunosorp). Binding of anti-TGEV spike or tag specific mAbs to wild type and 
mutant CoV RBD was assayed using purified mAbs or hybridoma supernatants. The CoV 
RBD-Fc fusion protein produced in serum free supernatants was bound to plastic and mAb 
binding was monitored by optical density (OD492nm). At least four RBD-Fc concentrations 
ranging from 1 to 10 µg/ml were used in duplicate and average binding was deduced after 
correcting the background binding. ELISA was also used as a test to determine purification 
efficiency in antibody affinity based purifications of soluble proteins.  
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3.6 Flow cytometry  
Flow cytometry was used to characterize cell surface expression of APN, as well as its 
interaction with TGEV-RBD on the surface of 293T, BHK21, and CHOK1 cells. Briefly, 
cells washed with ice cold PBS, were detached from the plate surface using 0.02% EDTA 
solution. After brief sedimentation at 1400rpm, cells were resuspended in flow cytometry 
(FACS) buffer (0.5-1%BSA in PBS). Cells were counted on haemocytometer and plated in 
conical wells of a 96 well plate at a density of 5x10
4
 cells/ well. Binding procedures were 
performed at 4
o
C. The TGEV-RBD-Fc fusion protein was added to wells with cells at the 
appropriate concentration in 20 µl of FACS buffer for binding to APN for 30 mins, followed 
by three centrifugal washes with FACS buffer. Subsequently, cells were stained with anti-
human IgG-FITC Ab (Invitrogen) and incubated on ice for 30 mins followed by 3 washes 
prior to analysis in the flow cytometer. 
APN expression on the cell surface was analyzed by FACS using either the anti-human APN 
mAb (WM15) or anti-HA mAb for pAPN (5 μg/ml). An anti-mouse IgG-FITC Ab 
(Invitrogen) was used for antibody detection.  
3.7 Cell surface APN crosslinking and immuno-precipitation 
Cell surface dimerization of wild type and pAPN mutants were analyzed by chemical 
crosslinking of cell surface proteins on transiently transfected 293T cells. Cells were 
transfected with recombinant pEF-HA vector with a cDNA encoding the membrane-bound 
pAPN protein and with a C-terminal HA peptide. Two days post-transfection, cells were 
washed twice with PBS and collected for flow cytometry analysis of pAPN expression and 
TGEV-RBD binding (Section 3.6). A water soluble and membrane-impermeable reagent 
bis[sulfosuccinyimidyl] suberate (BS
3
, Pierce), was used to crosslink proteins on the cell 
surface according to manufacturer‟s instructions. Briefly, cells were treated with 3 mM BS3 
for (30-60 mins at 4ºC) and the reaction quenched with 20 mM Tris-HCl pH 7.5 for 15 mins. 
Cells were washed, sedimented, and resuspended in ice-cold lysis buffer (50 mM Tris-HCl 
pH 7.4, 1% Triton X-100, 300 mM NaCl, 1 mM DTT, 1 mM PMSF, 1 mM EDTA) by brief 
shaking. Solublized pAPN proteins were immuno-precipitated with anti-HA mAb, analyzed 
by SDS-PAGE followed by a western blot using the same mAb, an HRP-labeled secondary 
antibody, and the ECL plus detection kit (GE Healthcare). 
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3.8 APN catalytic activity assays 
Commercially available leucine-paranitroanilide (L-pNA) substrate (Sigma) was used in a 
standard spectrophotomteric assay to characterize catalytic activity of soluble or cell surface 
aminopeptidase N. Assay was performed in 96 well plates with 100ul reaction volumes/well 
prepared in PBS pH 7.5. FPLC purified soluble APN (5µg/ml; 40nM) were added to wells in 
duplicates, either alone or with increasing amounts of soluble TGEV/PRCV S proteins. L-
pNA substrate was added to the reactions at a final concentration of 1 mM at 4
o
C. Plates were 
incubated at room temperature and OD at 405nm was measured at different instances to 
determine the amount of released pNA byproduct of APN catalysis. Background OD of wells 
without APN was subtracted to determine specific catalytic activity. Activity of cell surface 
expressed APN was similarly analyzed using 0.5x10
5
cells/wells. 
3.9 Generation of TGEV mutants 
Methods towards engineering coronavirus genomes in bacterial artificial chromosomes 
(BACs) are well established (Almazan et al., 2000, Almazan et al., 2008) and have been 
followed in the research work of this thesis to develop and rescue TGEV mutants. A scheme 
of steps involved in developing the mutants has been depicted in Fig 3.3A. Firstly, a 
recombinant cloning vector pGEM-T, which carried a copy of the full length cDNA of TGEV 
S (PUR46MAD), was used as a template to generate S protein mutants (Section 3.4). Using 
the PacI and MluI restriction enzymes, the mutated S fragment was transferred to an 
intermediate recombinant BAC plasmid, pBeloBAC11-TGEV
∆claI 
(Fig. 3.3). This BAC 
plasmid carried an engineered cDNA copy of the full length TGEV genome, except an 
element (ClaI-ClaI fragment) which is toxic to bacterial culture. This modification (ClaI 
fragment) was separately maintained in another BAC construct, (pBAC-TGEV
claI
) and 
introduced in to the intermediate BAC plasmid in the last cloning step to make the final full 
length infectious construct, pBeloBAC11-TGEV
FL
 (Fig. 3.3B). Mutations were verified by 
sequencing the resultant BAC plasmids using primers amplifying a stretch of S. Colony PCR 
and restriction digestion pattern analysis was used to verify the correct orientations of the 
inserts and the BAC stability throughout the steps in engineering of the final TGEV clone. 
Due to low copy number (1 or 2 per cell) and the need for suitable amounts of the 
recombinant BAC constructs midiprep plasmid DNA kit (Qiagen) was used with special 
recommendations for BAC system. For BAC and insert DNA purification, agarose gel 
extraction was done with the QIAEX II Gel extraction kit (Qiagen). 
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Figure 3.3. Generation and rescue of mutant TGEV. A Scheme of procedures followed to generate TGEV 
mutants starting from site directed mutagenesis of the S-cDNA, followed by its transfer to a stable intermediate 
pBAC-TGEV∆ClaI vector disarmed for a toxic fragment. A final infectious BAC vector is generated for 
transfection of BHK-pAPN cells for generation of recombinant TGEV with mutation in the S protein, 
Transfected BHK-pAPN cells are layered on fresh monolayer culture of ST cells for amplification. The virus 
titers are determined by plaque assays. B. Cartoons showing details of the cloning strategy of using the BAC 
vectors. Figure adapted from a published source (Almazan et al., 2000). 
 
Rescue and characterization of the respective TGEV mutants, was carried out in mammalian 
cells. Highly pure preparations of pBeloBAC11-TGEV
FL
 constructs prepared with the Large 
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Construct kit (Qiagen) were transfected into monolayers of BHK-21 cells expressing pAPN 
on their cell surface (BHK-pAPN cells). The transfection reagent, Lipofectamine 2000 
(Invitrogen) was used following established protocols (Almazan et al., 2008). After 6 hours of 
transfection, transfected cells were detached by brief trypsin treatment and layered on a ST 
cell monolayer. When a cytoptahic effect was seen (2-3 days post transfection), supernatants 
were collected for virus titrations using plaque formation assays.  
3.10 Cytopathic effect (CPE) assays 
CHOK1 cells were seeded on 96 well plate at a cell density of 5x10
4
 cells/well in E-MEM 
supplemented with 10% dialyzed FCS. The following day, cells were inoculated with 
increasing dilutions of the viral stock. CPE was observed 48 hours after infection, following 
fixing in 10% formaldehyde for 1 hour and cell staining using crystal violet solution. For 
quantification of viruses in supernatants, titrations utilized plaque formation assays on ST cell 
monolayers. ST cell monolayers were seeded on 24-well tissue culture plates and inoculated 
with serial dilutions of supernatants in DMEM supplemented with 2% FCS. After 90 minutes 
absorption, monolayers were washed with media and fed with semisolid overlay media (0.7% 
agar in media). Plates were incubated for 2 days followed by crystal violet staining for plaque 
counting. 
3.11 Crystallography methods and tools 
Crystallography of soluble APN ectodomains and their complexes with CoV S length 
variants followed the workflow shown in (Fig. 3.4). 
3.11.1 Protein Concentration  
After obtaining pure homogenous protein sample following gel filtration chromatography 
(Section 3.3), the sample fractions were pooled together for concentration in centrifugal 
concentrator units (Millipore, PAL life sciences). Samples were centrifuged in these 
concentrators at the recommended speed and10
o
C in either SS34 rotor (Sorvall) or bench-top 
centrifuge (5810R, Eppendorf). Concentration procedure was continued to reach a protein 
sample of 15-20 mg/ml, which was used for setting up crystallization screening trials.  
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Figure 3.4. Strategic workflow for structure determination of APN and complexes with CoV S 
proteins. The flowchart points out important technical milestones to during protein preparation in 
mammalian cells, their crystallization and structure determination. The recombinant cDNA is cloned in a 
mammalian expression vector with a suitable tag (Fig 3.1). Protein expression is first tested by transient 
expression in HEK-293T cells. This is followed by stable expression and selection of CHOLec clone, which 
is then scaled up in roller bottle cultures for periodic collection of supernatants and media replenishment. 
Supernatants are run through affinity columns to purify proteins in the first round and later by a size 
exclusion step. The concentrated proteins are crystallized using several crystallization kits and hit conditions 
are repeated to improve crystals that are then exposed to X-rays at the synchrotron beamlines to perform 
diffraction data collection. Crystal structures are determined following different methodologies.  
 
3.11.2 Crystallization screening  
Commercially available crystallizations kits (Jena Biosciences and Hampton Research) were 
used in the screening of crystallization conditions for all proteins in this Thesis work. All 
trials were done with the sitting drop method using 96 well crystallization plates. 
Crystallization drops were set up using a liquid handling robot (TECAN). Fig. 3.5 shows a 
schematic diagram of sitting drop technique that allows vapour diffusion mediated 
crystallization of proteins (Bergfors 1999). For co-crystallization of protein complexes, 
equimolar mixtures of the interacting proteins were incubated overnight before setting up 
crystallization screens. Crystallization screening plates were incubated at constant room 
temperature of 22
o
C. Various crystal forms were obtained for different proteins and 
complexes. The kit screen solutions giving protein crystals were usually modified for crystal 
improvement for performing X-ray diffraction. 
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3.11.3Crystal data collection and processing 
X-ray diffraction data collection is performed with frozen crystals at -160
o
C to prevent X-ray 
crystal damage. Crystals must be transferred to a cryoprotectant solution prior to its freezing 
(Rodgers, 1994). We usually dialyze the crystals against a solution that contains 
cryoprotectant mixed with the crystallization solution. These cryoprotectants include ethylene 
glycol, or glycerol. The amount of cryoprotectant was screened beforehand using a liquid 
nitrogen stream.  
 
 
 
Figure 3.5. Sitting drop vapour diffusion method of protein crystallization. Equal volume of purified 
protein and reservoir solution is placed over a platform in the sub-well of a 96 well crystallization plate. The 
well contains the reservoir or crystallization solution which contains precipitants at higher concentration than 
in the drop. The phenomenon of crystallization occurs during gain of solution equilibria in the system which 
occurs by gradual vapour diffusion of water and/or precipitant from the drop solution. This renders the 
proteins supersaturated, and thereby crystallized with an appropriate crystallization solution (Bergfors 1999). 
 
Using X-ray synchrotron sources at ESRF (Grenoble, France), Swiss-SLS facility and ALBA 
(Barcelona, Spain), diffraction data were collected for single protein crystals. When a crystal 
is exposed to an incident X-ray beam, the result is a diffraction pattern, which consists of 
millions of spots that constitute the raw data. Each of the signals is determined by three 
parameters that are necessary to obtain the electron density map. These parameters are the 
position, intensity and phase of the waves forming each signal. Diffraction data are first 
processed to determine the index (hkl values) and respective intensities of the diffraction 
spots. We used the MOSFLM (Leslie, 1992) and XDS (Kabsch, 1993) processing programs. 
The objective of these processing was to acquire the index (hkl values) and respective 
intensities of the diffraction spots. The data were subsequently scaled using the program 
SCALA (1994). The scaling process sets all diffractions measurements on a common scale 
and produces an internally consistent set of data (Evans, 2006). 
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3.11.4 Structure solution and refinement 
Crystal structure determination needs the resolution of the phase one of the major drawbacks 
of X-ray crystallography. To solve this problem, the two techniques frequently employed are 
Multiple Isomorphous replacement (MIR) and Multiple-wavelength Anomalous dispersion 
(MAD). MIR is based on the incorporation of heavy metals in the crystallized protein without 
changing its native structure, and hence the crystals are isomorphic. Data for both the native 
and heavy atom incorporated crystals are collected and then the location of the heavy atom in 
the structure is determined using Patterson difference map. This helps in elucidating both the 
amplitude and the phase of the heavy atom. MAD (Hendrickson and Ogata, 1997) method 
however records anomalous diffraction at different wavelengths of the coherent X-rays at the 
synchrotron. Another method that does not require the use of heavy atoms is Molecular r 
Replacement (MR). This method makes use of the structural similarities shared by the 
members of a family of proteins. A known structure can be used to determine a similar 
crystal structure. The position and orientation of the unknown molecule within the unit cell 
can be determined using the MR method and thus solve its structure. 
The results of phase and structure determination is a three dimensional maze of protein 
electron clouds known as the electron density map. Based on this map and with the amino 
acid sequence, an initial model of the protein structure is constructed, which after undergoing 
a series of refinement results in a final model. This latest model or protein structure consists 
of the Cartesian coordinates of each atom of the molecule models except the hydrogen atoms. 
An important property of the final model is the resolution, that is, the minimum distance can 
be defined. The unit of this parameter is the Amstrong (Å), and the lower the value will be 
higher the resolution, i.e., the electron density map will be of higher quality. 
Following above methods, structure of a Seleno-methionine (Se-Met) derivative of pAPN 
was solved using MR and Single-wavelength Anomalous Dispersion (SAD) methods. This 
Se-Met pAPN protein was deglycosylated by Endoglycosidase-H treatment (pAPNeh). MR 
was carried out with the program PHASER (Read, 2001) using domain I, II and -III of the 
tricorn interacting factor F3 (TIF3, PDB code Z1W1) as search models. TIF3 domains share 
~30% residue identity with the N-terminal three domains of the pAPN ectodomain. This gave 
a partial structure which was then completed following the MRSAD protocol implemented in 
the Auto-Rickshaw server (Panjikar et al., 2009). The final structure included two pAPN 
molecules in the asymmetric unit, which were then adjusted manually and refined with 
phenix.refine (Adams et al., 2010) using data extending to 2.5 Å resolution. The pAPN final 
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structure comprises residues 60-963 of its ectodomain and a zinc atom coordinated in the 
enzyme‟s active site. The pAPNeh structure formed the basis of MR applied to determine 
structure of the other pig and human APN ectodomain structure. Two ensembles including 
either DI-DIII or isolated DIV were used for structure determination with PHASER. 
Structures were refined using phenix.refine. In all APN structures, the N-terminal 25-30 
residues were very disordered and hence were not included in the final models. 
The structure of the co-crystallized complex that includes the PRCV-RBD bound to the 
pAPN was determined by MR using known pAPN structure (described above) and the TGEV 
RBD as search models. The TGEV-RBD structure was previously determined by the group in 
complex with the Fab fragment of the neutralizing 1AF10 mAb (PDB code 4F2M). MR 
solutions were obtained for the two pAPN molecules (chains A and B) in the asymmetric unit 
and for one RBD molecule (chain E). The three molecules were manually adjusted and 
refined using the phenix.refine program. The second RBD molecule (chain F) bound to 
pAPN molecule B was built manually into the electron density map. The N-terminal 282 
residues in the PRCV SH3 variant were highly disordered or degraded during crystallization, 
and they are absent in the structure. The complex structure was refined with the phenix.refine 
applying solvent corrections, NCS, refinement of individual coordinates and atomic 
displacement parameters combined with TLS. The current model includes amino acids 60-
963 of the pAPN ectodomain with the zinc metal ion in the catalytic site, and residues 283-
426 of the PRCV S (homologous to TGEV S residues 507-650 that defined the TGEV RBD 
structure). All the residues are within the allowed regions of the Ramachandran plot.  
 
  
 
 
 
 
CHAPTER 4 
 
 
 
 
 
 
 
  
 
 
 45 
 
4. RESULTS 
4.1 Expression and purification of soluble APN ectodomains and CoV 
spike protein. 
4.1.1. Cloning and expression 
APN and CoV S proteins are heavily glycosylated, so we have produced them in mammalian 
cells. The cDNA coding for the APN ectodomains, including residues 36-963 of the pig 
(pAPN) and 33-967 of the human (hAPN), were PCR amplified from their respective cDNA 
templates (Fig.3.2A). Similarly, the coding sequences for different length variants of TGEV 
and PRCV CoV S (Fig. 3.2B) were prepared using the respective cDNA (Sánchez et al., 
1990). Recombinant cDNA amplicons for APN and a small TGEV spike length variant RBD 
(Fig. 3.2B) were individually introduced into a vector, pBSKS-D (Fig. 3.1A) bringing them in 
frame with an exogenous N-terminal IgK leader sequence (for cellular secretion) and an HA 
epitope. The PRCV S length variants (Fig. 3.2B), SH1 and SH3 (both containing the antigenic 
site A) contained an endogenous secretion signal peptide at their N-termini. The recombinant 
DNA were then transferred to vector that was derived from pEF-BOS (Fig. 3.1B) and cloned 
in frame with a Flag or HA epitope (monomeric), or the human IgG1 Fc region (Fc, dimeric) 
at the C-terminus. Thrombin recognition sequence was introduced between the protein and the 
C-terminal tags. S glycoprotein of PRCV exhibits 96% sequence identity to corresponding 
fragments in TGEV.  
For transient protein expression, recombinant pEF vectors were transfected into HEK293T 
cells following the calcium phosphate method (Jordan et al., 1996). After 3-4 days of protein 
production in either DMEM supplemented with 10% FCS or serum free optiMEM media, 
protein concentrations were determined using ELISA with antibodies that bind to the CoV S 
or to the different tags. 
 Having confirmed expression in transiently transfected HEK293T cells, the recombinant 
cDNA in pEF vector were cut with SalI-NotI enzymes and transferred into the unique XhoI 
and NotI sites in pBJ5GS vector (Fig 3.1C). These recombinant pBJ5GS constructs were used 
to develop stably expressing CHOLec cell clones following glutamate synthetase expression 
system. ELISA was performed to screen for protein expressing clones growing at 30µM 
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MSX. Protein expression was scaled up by culturing highly expressing clones in roller bottles, 
with periodic collection of supernatant and replenishing with fresh selection media. 
A 
 
B 
 
C 
 
D 
 
 
 E 
 
 
 
Figure 4.1. Analysis of affinity purified recombinant proteins. 10% SDS-PAGE of elution fractions 
collected from mAb-Sepharose columns. Loaded with supernatants from CHOLec cell transfectants 
expressing pAPN (A), hAPN (B), PRCV SH1 (C), PRCV SH3 (D) and TGEV S RBD (E). Size of the 
molecular weight markers loaded in the left track is shown. 
 
4.1.2 Protein purification 
Supernatants collected from CHOLec cell clone for respective proteins were first purified by 
affinity chromatography using mAb coupled to Sepharose (Fig. 4.1). TGEV RBD and PRCV 
SH1 and SH3 length variants were purified using the 6A.C3 mAb (against antigenic site A) 
while pAPN and hAPN were purified with the HA 12A.C5 mAb. After supernatant loading, 
the columns were washed with TBS pH 8.3 and the proteins were eluted with 20-40mM 
glycine buffer (pH 2.8 for 6A.C3 and pH 3.0 for 12A.C5 column) and quickly pH 
neutralized. The purification efficiency was determined by ELISA. Concentration of the 
protein in the elution fractions was determined by OD at 280 nm and the size and purity of 
the proteins by SDS-PAGE (Fig. 4.1). 
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Figure 4.2. Size exclusion purification of recombinant proteins. Overlaid chromatograms recorded 
during purification of the indicated soluble proteins run through a Superdex 200 (16/60) column. 
Exclusion volumes and molecular weights (kD) of markers indicated. 
 
Final purification of the affinity purified protein samples were performed following size 
exclusion chromatography on Superdex 200 column fitted to an “Akta-purifier” (GE 
healthcare) (Fig. 4.2). The mobile phase buffer included 20 mM HEPES, 150 mM NaCl 
(HBS), pH 7.5. Concentrations of the purified proteins were determined by OD at 280 nm.  
 
 
 
Figure 4.3. Deglycosylation of PRCV SH3 length variant. 10% SDS-PAGE of Endoglycosidase-H treated 
(+) and untreated (-) SH3 length variant. Protein was expressed in CHOLec cells. Size of the molecular weight 
markers loaded in the left track is shown. 
 
Purified PRCV SH1 and SH3 depict a slightly higher molecular weight in SDS-PAGE than 
expected likely related to glycosyltaions (Fig. 4.1 and Fig. 4.4). Proteins were prepared in 
CHOLec cells so that they should bear high mannose N-linked glycosylation sensible to 
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Endoglycosidase H (Endo-H). This was verified by overnight Endo-H treatment at 30
o
C 
followed by SDS-PAGE analysis (Fig. 4.3). In the size exclusion chromatograms, the APN 
apparent molecular weight (Fig. 4.2) was about twice of their size in SDS-PAGE (Fig. 4.4), 
indicating protein dimerization in solution. The dimerization of the pAPN and d hAPN 
protein in solution was confirmed by analytical ultracentrifugation (data not shown).  
A 
 
B 
 
C 
 
D 
 
 E 
 
 
Figure 4.4. Analysis of the size exclusion purified recombinant proteins.10% SDS-PAGE  of elution 
fractions collected from size exclusion columns of affinity purified pAPN (A) and hAPN (B), SH1 (C), SH3 
(D), and TGEV RBD (E). Size of molecular weight markers loaded in the left track is shown.  
 
4.2 Crystallization of the APN ectodomain and Structure 
determination 
4.2.1 Crystallization of the isolated APN ectodomains  
Chromatograms fractions with homogenous and pure proteins (Fig. 4.4) were pooled and 
concentrated (~15 mg/ml) using centrifugal concentrator units. Both glycosylated and Endo-
H treated pAPN and hAPN were used to set up screens for crystallization trials following 
vapor diffusion sitting drop method (Section 3.11). 
Native glycosylated pAPN was crystallized at 21
o
C with a reservoir solution containing 20% 
PEG3350, 100 mM sodium acetate pH 5.6 (Fig. 4.5A). Crystals of Endo-H treated pAPN 
 49 
 
(pAPNeh) and its seleno-methionine conjugate (pAPNeh-Se-Met) were obtained at 21
o
C 
(Fig. 4.5B) in reservoir solution containing 5% PEG-1000 and 10%PEG-8000. Single crystals 
of glycosylated human APN were first obtained in a condition with 20% PEG10000, 100 mM 
HEPES, pH 7.5, but these crystals did not diffract X-rays.  
A 
 
B 
 
C 
 
D 
 
Figure 4.5. Crystallization of APN. A. Cuboidal crystals of native glycosylated pAPN. B. Needle-like 
crystals of Endo-H treated pAPN. C and D. Plate shaped and cuboidal crystals of glycosylated hAPN 
with 1mM curcumin.  
 
Besides crystallizing APN alone, I carried out co-crystallization of hAPN and pAPN with 
catalysis inhibitors (bestatin, actinonin, and curcumin) and/or CNGRC peptide ligands, but 
diffracting crystals could not be obtained in most cases. Only human APN gave suitable 
crystals in a mixture with 1mM curcumin (Sigma) in two different crystallization conditions: 
i) 20% PEG4000, 200mM lithium sulphate, 100mM Tris-HCl pH8.5 (Fig. 4.5C) and ii) 20% 
PEG6000, 59mM imidazole-HCl pH8.0 (Fig. 4.5D). Crystals were frozen in crystallization 
solution containing 20% ethylene glycol as cryoprotectant and transported frozen to the 
synchrotron for diffraction data collection. 
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4.2.2 Crystallization of the pAPN in complex with TGEV and PRCV CoV S 
variants 
Sitting drop method was used to prepare crystallization screens of pAPN in complex with 
SH1, SH3 and RBD length variants of TGEV and PRCV S protein. Complexes were prepared 
with combinations of either glycosylated and/or deglycosylated forms of both the proteins. 
Crystals appeared only in trials performed with an equimolar mixture of pAPN and RBD 
(both in glycosylated form) at a final concentration of 13 mg/ml, and in a crystallization 
solution of 20% PEG-4K, 200 mM lithium sulfate and 100 mM Tris buffer pH 8.5 (Fig. 4.6). 
Crystals were transferred to crystallization solution containing 20% ethylene glycol and 
frozen for diffraction data collection at the ID29 beamline. 
 
 
 
 
 
 
 
 
 
Figure 4.6. Crystals of pAPN-SH3 complex. Photographs show multiple crystals (left), bouquet 
shaped crystals with possible high twinning (middle) which was optimized to single crystals (right) by 
seeding in a 24 well crystallization plate.  
4.2.3 Structure determination 
The crystal structure of a Seleno-methionine derivative of pAPN was solved first. Diffraction 
data at different wavelength was collected with some of the few crystals (~10) obtained with 
the pAPNeh-Se-Met protein in the ID14-4 beamline (ESRF). Crystals suffer from radiation 
damage, so that only the Se peak wavelength was collected with three crystals; one complete 
dataset including data to about 2.5Å was finally processed (Table 4.1). No clear Se peaks 
were observed in Patterson maps determined with anomalous data. Simultaneously, we 
started crystal structure determination of the pAPN ectodomain using the pAPNeh-Se-Met 
diffraction data and the homologous domains of the TIF3 following MR (Materials and 
Methods).  DI-DII-DIII of TIF3 share 30-35% sequence identity with the homologous pAPN 
domains.  This three-domain module was used as a search model and gave two distinct 
solutions in the molecular replacement search, which corresponded to the two molecules in 
the asymmetric unit.  No solution was found with the TIF3 DIV, which is expected to be 
divergent from the pAPN DIV.  To determine the structure of the complete pAPN 
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ectodomain we followed the MRSAD protocol of the Auto-Rickshaw server (Panjikar et al., 
2009).  The resulting model was adjusted manually to the electron density maps and refined 
with phenix.refine (Adams et al., 2010) using data to 2.5 Å resolution (Table 4.1). The pAPN 
final structure comprises residues 60-963 of its ectodomain and a zinc atom coordinated in 
the enzyme‟s active site.  
Diffraction data for the native glycosylated pAPN and hAPN crystals were collected in the 
ID23-1 (ESRF) and PXII (SLS) beamlines (Table 4.1), whereas the crystal diffraction of the 
pAPN in complex with the PRCV-RBD was performed in the ID29 (ESRF) beamlines. Two 
independent ensembles including either DI-DIII or isolated DIV of pAPNeh were used for 
APN structure determination by MR using PHASER. The TGEV-RBD structure (PDB code 
4F2M) was also used for determination of the pAPN-RBD structure such as described in 
Materials and Methods. Structures were refined using phenix.refine and adjusted manually. In 
all APN structures, the N-terminal 25-30 residues were very disordered and hence were not 
included in the final models. The PRCV RBD includes residues 283-426 of the PRCV S 
(homologous to TGEV S residues 507-650 that defined the TGEV RBD structure).  The N-
terminal 282 residues of the SH3 protein used for the crystallization of the complex were 
disorder or more likely degraded. On the portion corresponding to the RBD was defined in 
the electron density maps after structure refinement. All the residues are within the allowed 
regions of the Ramachandran plot in the crystal structures included in (Table 4.1). 
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Statistics pAPN pAPNeh  
(Se-Met) 
hAPN pAPN-RBD 
Data Processing     
Space group P1 P21 P212121 C2 
Cell dimensions     
   a, b, c (Å) 78.7, 78.8, 223.9 66.5, 215.7, 78.6 127.1, 168.9 ,244.2 220.86, 87.94, 176.91 
 () 99.7, 92.6, 111.3 90.0, 91.9, 90.0 90, 90, 90 90, 90.54, 90 
Wavelength 0.87260 0.97950 1.00000 0.97914 
Resolution (Å) 25-2.0 25-2.5 20-2.6 25-3.2 
Unique reflections 322701 73986 160355 53840 
Redundancy 2 (2.0) 4.1 (3.9) 4.2 (4.1) 3.0 (3.1) 
Completeness (%) 97.5 (96.6) 97 (95.5) 99.79 (99.9) 96 (97) 
Rsym or Rmerge 87.5 (20.7) 10.5 (35.6) 5 (35.3) 5.7 (37.7) 
I/  8.5 (3.6) 6 (1.8) 12.3 (2.1) 5.5 (2.1) 
     
Refinement      
Resolution (Å) 25.0-2.0 25.0-2.5 20-2.6 25-3.2 
Rwork / Rfree 17.14/20.9 19/22.9 18.11/21.5 20.1/24.5 
No. of atoms     
 Protein 28817 14292 29182 16697 
Carbohydrates 726 252 1417 365 
     Ligands     
     Ion (Zn) 4 2 4 2 
 Water 4899 381 707 3 
Average B-factors     
 Protein  13 20 55 95 
Carbohydrates 32 37 101 125 
     Ligands     
Ions (Zn) 6 17 43 75 
  Water 26 20 47 60 
R.m.s deviations     
    Bond lengths (Å) 0.006 0.009 0.004 0.003 
    Bond angles () 1.022 1.28 0.77 0.880 
Ramachandranplot
a 92/4/0/0 92.4/7.1/0.4/0 97/2.8/0/0 81.7/16.1/2.2/0.0 
Table 4.1. Data collection and refinement statistics. Values for highest-resolution shell are shown in 
parentheses. 
a
Percentage of residues in most favored/allowed/generously allowed/disfavored 
regions are shown. 
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4.3 Crystal structures of APN ectodomains 
The human and pig APN ectodomains exhibit a hook-like topology in crystal structures 
(Fig.4.7). The N-terminal HA tag and about 30 residues that follow it (Fig. 3.2A) were much 
disordered indicating a highly flexible region in the membrane proximal end. APN 
ectodomain is composed of four domains (Fig. 4.7B). The first domain (DI) exists as a 
twisted β-barrel domain of about 200 residues (Fig. 4.7A and Fig. 4.8). This domain 
assembles as a packing of one extended β-sheet against two shorter β-sheets with three and 
four β-strands (Fig. 4.7A). Domain II (DII) adopts a thermolysin-like fold. The DI β-sheet 
with four strands stacks on the top of a five stranded β-sheet of DII in such a way that the 
catalytic groove (in DII) is covered from the top (Fig.4.7 B). This groove is formed at the 
junction between the DII N and C-terminal subdomains (Fig. 4.7A), two long α-helices 
bearing residues that coordinate zinc ion are at the bottom of the groove. The third domain 
(DIII) is a small (90 aa) β-barrel domain heavily glycosylated in ectodomain‟s middle 
portion, at the turn of the hook (Fig.4.7B). DIII carries a conserved N-linked glycan on a long 
loop which is disordered in the pAPN. This glycan interacts with domain II and IV (Fig. 
4.7B). With about 330 aa (Fig. 4.8), the fourth APN domain (DIV) is the largest among the 
four domains and is composed of alpha-helices. Albeit, being highly divergent among the M1 
family of the peptidases, overall DIV conformation remains preserved. A double layer of 
helices in DIV adopts a circular configuration forming a bowl-like structure (Fig. 4.7B) 
(Addlagatta et al., 2008). The N and C-terminal portions of the domain IV contact DIII and 
they are bridged by the last, long α-helix (α29) of the ectodomain. DIV is an assembly of 8 
repeats of a helix-turn-helix motif with either a HEAT or ARM conformation (Nguyen et al., 
2011). In APN, DIV has 1 ARM and 7 HEAT repeats. The single ARM repeat is formed by 
helices α25, α26 and α27 (Fig. 4.7B) and its conformation varies between the hAPN and 
pAPN ectodomain structures (Fig. 4.8). The ARM repeat is the most variable region between 
hAPN and pAPN ectodomains, and can contact the peptide substrate bound to the active site 
(see below). The concave inner side of the DIV bowl faces the DII active site (Fig. 4.6A), 
enlarging the cavity below the coordinated zinc ion, where the substrate is accommodated 
during catalysis.  
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Figure 4.7. Crystal structures of APN ectodomains. A Ribbon diagrams of the glycosylated pAPN and 
hAPN structures with domains (D) in orange (N-terminal DI), yellow (DII), red (DIII) and green (C-terminal 
DIV), and the N-terminal end (n) near the cell membrane. Asn residues in N-linked glycosylation sites and 
modeled glycans (grey) in the structures are shown as spheres. The zinc metal ions at the active site in DII are 
shown as cyan spheres. The approximate location of N- and C-terminus of the structures, and the cell 
membrane are marked. B. Stereo view of the individual domains that compose the APN ectodomains with 
similar orientation as in A. The three -sheets of DI and the two subdomains (N and C-terminal) of DII are 
shown with distinct colors. Helix and -stands are numbered as in Fig. 4.8.  
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Figure 4.8. Alignment of human and pig APN ectodomains. Structure-based sequence alignment of the 
human and pig APN with conserved residues highlighted in red. The individual domains of the hAPN and 
pAPN structures were aligned with the program Modeller using a gap penalty of 3. Secondary structure 
elements are shown above and below the sequences. Residues involved in peptide binding and hydrolysis 
at the active site are in yellow, with the residues coordinating the zinc ions marked with an asterisk. 
Residues involved in protein dimerization and CoV binding are in green and blue, respectively. Each 
domain‟s first residue is labeled. Figure prepared with ESPript 3.0 (http://espript.ibcp.fr). 
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4.3.1 The dimeric conformation of the APN ectodomain 
The dimeric APN assembly is well preserved in both hAPN and pAPN ectodomain crystal 
structures (Fig. 4.9A). The APN ectodomains behave as dimers in solution (Fig. 4.2). APN 
crystals must thus grow by contacts between preformed dimers as they appear in the crystals 
grown with different protein samples and crystallization conditions. The exposed convex side 
of DIV contacts the same face of another DIV in a neighboring APN molecule (Fig. 4.9A). 
Approximately 950 Å
2
 of each monomer is buried at the dimer interface, indicative of a 
stable protein-protein interaction that engaged only DIV residues. The protruding 22-23 
inter-helical region of one monomer contacts the bottom of domain IV bowl of the other 
monomer, thus closing ~10Å pore towards the internal APN cavity (Fig. 4.9B). Dimerization 
must prevent substrate access to the catalytic active site through the domain IV pore, an entry 
point advocated for other monomeric M1 aminopeptidases (Addlagatta et al., 2008). A 
tryptophan residue conserved in mammalian APN (W839 in hAPN, Fig. 4.8) appears to be a 
key dimerization residue and contacts seven residues in the neighboring monomer. 
Dimerization interface and the involved residues are relatively conserved among pAPN and 
hAPN structures (Fig. 4.8 and Fig. 4.9C). Hydrophilic interactions on the dimerization 
surface periphery differ between hAPN and pAPN (Fig. 4.9C).  
 
 
 
Figure 4.9. Conserved dimeric structures of the mammalian APN ectodomains. A. Ribbon 
representation of the dimeric pAPN and hAPN structures. Lateral and frontal views of the dimer 
interface are shown in B and C, respectively. Side chains of residues buried at the dimer interface are 
shown with sticks; residues involved in polar or non-polar interaction are with magenta or orange 
surfaces, respectively. Buried residues by dimerization in the different crystal structures have been 
shown in Table A (Appendix). 
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4.3.2 Demonstrating the relevance of the crystallographic APN homodimer 
Mammalian APN has been reported to exist as membrane bound dimers on the cell surface 
(Hussain et al., 1981). Soluble hAPN and pAPN ectodomain dimerization was noticed before 
by comparing gel filtration (Fig. 4.2) with SDS-PAGE (Fig. 4.4). In all the APN crystal 
structures presented here the dimeric assembly of the ectodomain is well preserved and might 
be representative of the functional cell membrane dimers. To verify this crystallographic 
result, a mutation was introduced at the dimer interface of pAPN using site directed 
mutagenesis. This mutation substituted a threonine for valine at position V835 (Fig. 4.8) 
resulting in an N-linked glycosylation at Asn833 (N833glyc), near the center of the dimer 
interface (Fig. 4.9C). The soluble mutant was produced in HEK-293T cells and its size 
exclusion profile depicted a monomeric behavior with a molecular weight about half that of 
wild type pAPN dimer (Fig. 4.10A). The larger size of the N833glyc mutant compared to 
wild type pAPN in electrophoresis indicates additional glycosylation (Fig. 4.10A, inset).  
A 
 
B 
 
Figure 4.10. Biochemical and immune-analysis of the crystallographic APN dimer. A. Size exclusion 
chromatography of the 293T expressed soluble ectodomains of pAPN and a mutant (N833glyc) protein with 
an N-linked glycan in Asn833 at the dimer interface (Fig. 4.9C). Continuous lines show optical density (OD) 
at 280 nm for the elution volume, determined by ELISA with an anti-HA mAb. The inset shows immune-blot 
of the pAPN and the N833glyc mutant.  Size (kDa) and elution volume/migration of molecular weight 
markers are indicated in both panels. B. Analysis of cell surface pAPN dimerization by chemical 
crosslinking. Immuno-blot of lysates of BS3 treated 293T expressing membrane bound pAPN wild type and 
mutant proteins or mock transfected cells (293T). Reaction time (min) is indicated at the top of each track, 
and migration of molecular weight markers (kDa) are on the left. 
 
Besides, we also analyzed cell membrane pAPN dimerization by BS
3
 crosslinking of surface 
wild type and N833glyc pAPN proteins (Fig.4.10B). A protein band consistent with pAPN 
dimers was only observed in crosslinked pAPN samples, indicating that inclusion of a glycan 
in the dimer interface prevents protein dimerization, and demonstrating the relevance of this 
region in APN homodimer formation.  
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4.4 The dynamic conformation of the APN ectodomain 
 Albeit the dimeric hAPN and pAPN assembly was preserved in various crystals, the 
conformations of the monomers differed among the crystal forms (Fig. 4.11A). The distance 
between the N-terminus of the ectodomains that formed the dimer increased from 95 to 131 
Å in the structures (Fig. 4.11A). DI-DII are distant from DIV in the open conformation of the 
APN monomer (Fig. 4.11), and the zinc ion at the catalytic site is more accessible to the 
solvent. The DI-DII-DIII module swings 14
o
 towards DIV, closing the active site (Fig. 
4.11B). The hAPN structure adopts an intermediate conformation in the crystals (Fig. 4.11A). 
The distance between the N-terminus of each monomer in the dimer is 115Å, and the angle 
difference of DII with the closed conformation in the monomers is approx. 6
o 
(Table 4.2). 
Other reported crystal structures of hAPN and pAPN also similarly showed closed and 
intermediate conformations respectively (Chen et al., 2012, Wong et al., 2012). The crystals 
provided different views of APN ectodomain dynamics. Closed ectodomains crystallized at 
low pH (<6.0), open at high pH (>8.0) and intermediate conformations crystallized at neutral 
pH (7.0-8.0) (Table 4.2). The contacts between the domain IV and other domains varied in 
the different APN conformations. Domain IV contacts with domain I or domain III changed 
markedly less (approx. 100-200 Å
2
 in the buried surface) than with DII (1000Å
2
); DII 
interaction with DIV thus mainly stabilized the closed APN conformation. There were no 
notable differences in the other interdomain contacts in the distinct APN conformations 
(Table 4.2). 
APN dimerization mediated by DIV-DIV interactions is preserved among open, intermediate 
and closed APN conformations (Fig. 4.11A). On the cell surface, the DI-DII-DIII module of 
the ectodomain must swing over DIV, which is fixed by dimerization. The movement of this 
module must be facilitated by the flexibility of polypeptide of ~30 residues which links DI to 
the transmembrane domain. The length of this polypeptide must limit the interdomain 
movement shown here with APN, which is less pronounced than that reported for 
endoplasmic reticulum aminopeptidase 1 (ERAP-1) (22
o
). The type of interdomain 
movement also differs between ERAP-1 and APN. The DIII-DIV module moves together 
relative to DI-DII module in ERAP-1, while DI-DII-DIII module swings over the fixed DIV 
in APN. Moreover, the hinge region in ERAP-1 is N-terminal in DIII, while in APN is N-
terminal in DIV. The DI-DII-DIII module can pivot at the beginning of the first (-13) or 
third (-15) DIV helix (Fig. 4.9), which are perpendicular to the swing angle (Fig. 4.11B). 
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These differences in APN dynamics compared to other aminopeptidases probably relate to 
dimer formation in APN, which is not observed in other members of the M1 family.  
A 
 
B 
 
 
Figure 4.11. Dynamic conformation of mammalian APN ectodomains. A. Ribbon diagrams of the dimeric 
APN ectodomain structures. Fragments of the CoV RBD bound to the open pAPN are shown in cyan and blue, 
with the tyrosine and tryptophan residues at the RBD tip as spheres in magenta. Distances between monomers 
were determined from the N-terminus of the first β-strand in DI. B. Interdomain movement between the open 
and closed APN conformation. The arrow indicates the swing movement of the DI-DII-DIII module toward 
DIV upon ectodomain closing in each monomer of the APN dimer, with DIV fixed by dimerization. The hinge 
residues at the N-terminus of α13 and α15 in DIV are marked with circles. Conformations of the ectodomains 
are shown below the structures. 
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 Interdomains Open 
(pAPN) 
Intermediate 
(hAPN)  
Closed 
(pAPN) 
Interdomain surface (Å
2
) I-II 1713 1752 1726 
 II-III 1244 1405 1341 
 III-IV 1018 1141 1131 
 I-IV -- -- 164 
 II-IV 761 1130 1763 
     
Interdomain angles  15 6 0 
     
Crystallization pH  8.5 8.0 5.6 
Table 4.2. Interdomain buried surface were computed with PISA server. Interdomain angles of the open 
and intermediate structures with respect to closed pAPN were determined after structure superposition based 
on DIV. Angles were computed based on the zinc ions at DII and the hinge residue at the C-terminus of DIV 
with the program coot.  
 
4.4.1 APN dynamics in catalysis  
The DII buried surface increases due to its interaction with DIV when the conformation 
changes from open to closed (Table 4.2), thus reducing accessibility of the active site cavity. 
It is already known that dynamics in M1 aminopeptidases are necessary for their catalytic 
activity and that closed conformations are believed to be their catalytically active forms 
(Addlagatta et al., 2006, Kochan et al., 2011). Though it remains still to be verified, how this 
structural switch connects to peptide processing. Conformation of the DII residues that 
participate in zinc coordination and peptide hydrolysis was conserved among the different 
APN structures presented here (Fig. 4.12A), indicating no changes in active site residues are 
required for catalysis. 
Crystal structures with closed and intermediate APN conformations are available in complex 
with substrates locked at their catalytic site (Chen et al., 2012, Wong et al., 2012). To analyze 
peptide processing, we modeled an AngIV substrate crystallized with hAPN {Wong et al., 
2012} in the active site of the open intermediate and closed APN structures shown here. In 
the closed pAPN, Phe893 is placed near the AngIV substrate and appears to lock the peptide 
in the active site for hydrolysis (Fig. 4.12B). Phe893 is found in the loop connecting α26 and 
α27 in single ARM repeat (Fig. 4.8) and in the closed structure fits over the substrate 
molecule hindering peptide translocation for further processing after hydrolysis. To proceed 
with product release from the active site, the lock needs to be released probably by DII 
displacement away from DIV. This may in turn facilitate removal of the Phe893 plug. APN 
dynamics hence must be indispensable for locking, processing and release of hydrolyzed 
peptide substrate at the active site groove.  
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B 
 
Figure 4.12. APN active site and ectodomain dynamics during catalysis. A. Ribbon diagram of the 
catalytic site of the four APN structures included in this report, with the side chains of DII residues involved in 
catalysis shown with sticks and the coordinated zinc ion as a cyan sphere. An acetate (ACY) was coordinated 
to the zinc in the pAPN structure, whereas the other structures had a water molecule (W, red sphere) that is 
involved in hydrolysis of the N-terminal residue of peptides substrates (Chen et al., 2012). B. Changes at the 
active site during APN ectodomain movements. The active site at DII (yellow) of the structures contains a 
modeled AngIV substrate coordinated to the zinc ion (cyan sphere).  Side chains of APN active site residues 
are shown with sticks, whereas AngIV is with a gray surface and residues in sticks with carbons in grey. 
Nitrogens in blue and oxygens in red. Hydrogen bonds are dashed lines. The helices of the ARM repeat (25-
27) of DIV (green) with the phenylalanine residue that contacts AngIV in the closed conformation are 
labeled. The crystal structure of the AngIV bound to the hAPN (PDB code 4FYS) was used to model it into 
the active site of the closed, intermediate and open structures by structural superposition based on DII.  
 
4.5 The RBD structure in TGEV and related coronavirus 
The RBD crystal structure of the TGEV S has been previously determined by our group in 
complex with a neutralizing antibody (PDB code 4F2M). TGEV S RBD adopts a β-barrel 
fold formed with two highly twisted β-sheets (Fig. 4.13A and C). 
Each of these β-sheets is composed of five β-strands. The N and C terminal ends are on the 
same side of the domain (terminal side) presumably lying close to the other S protein 
domains. Opposite to the terminal side, two β-turns (β1-β2 and β3-β4) form the tip of the 
barrel (Fig. 4.13A and C). A bent at the β-strand 5, crosses both the β-sheets and exhibits a β-
bulge (colored magenta in Fig. 4.13A and C) at N608. At one side of the β-barrel, all β-
strands run antiparallel to each other (colored cyan in Fig. 4.12 A and C), while on the 
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opposite β-sheet, only β1, β3 and β7 run parallel (in blue). N-linked glycans cluster at one 
side of the β-barrel. N- and C-terminal ends of the RBD, where other S protein domains lie, 
are opposite to the tip of the β-barrel. One aromatic residues, tyrosine or tryptophan, protrude 
from each of the two β-turns at the RBD tip (Fig. 4.13A and B). 
A 
 
 
B 
 
 C 
 
 
 
Figure 4.13. Structure of the RBD of TGEV S. A. Secondary structure elements of the RBD structures. β-
strands are shown with arrows and colored in blue and cyan, a β-bulge at the β-strand 5 is shown in magenta, 
helix with a red cylinder, coils with black lines, and disulphide bonds with green lines. B. Ribbon diagram of 
RBD protein structure with β-strands in light or dark blue, coils in orange, and helix in red. A β-bulge at β-
strand 5 is shown in magenta. N- and C-terminal ends on the terminal side of the structure are indicated in 
lowercase letters. The Asn residues at glycosylation sites and the attached glycans defined in the structure are 
shown as a ball-and-stick model, with carbons in yellow. Cysteine residues and disulfide bonds are shown as 
green cylinders. Side chains of the pAPN-binding Tyr and Trp residues in the loops at the β-barrel domain tip 
are shown in red. C. Surface representation of the TGEV RBD, residues engaged in direct receptor 
interaction in pink or red. 
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Figure 4.14. Sequence alignment of homologous CoV RBD. Alignment was carried out with the T-Coffee 
program (http://www.ebi.ac.uk/). RBD sequences of TGEV, canine and feline CoV (Alphacoronavirus1), 
human CoV (Alphacoronavirus), Bulbul-CoV (putative Deltacoronavirus) and IBV (Gammacoronavirus). 
Sequence of the TGEV RBD is numbered and its β-strands are shown with arrows. Residues in the two turns 
at the tip of the TGEV RBD β-barrel structure are indicated with a double T. 
 
Sequence alignment (T-coffee program) of the RBD regions from members of alpha-CoV1 
family (TGEV, CCoV, and FCoV) suggested a structure closely related to that of TGEV, 
including conformations of the loops (β1-β2 and β3-β4) at the β-barrel tip (Fig. 4.14). In case 
of the alpha-CoV HCoV-229E and HCoV-NL63 the β1-β2 and the β3-β4 loops at the RBD 
tip are different from the TGEV. The β1-β2 region has two Cys as in HCoV and lacks the 
exposed Tyr residue (Fig. 4.14). Moreover, the β3-β4 loop is seemingly shorter than that in 
TGEV. Sequence identities between the RBD of TGEV and IBV (Gammacoronavirus) or the 
Bulbul-CoV (tentative Deltacoronavirus) are relatively large (approximately 25%) and 
similarities are prominent mostly in the β-strands and at the RBD C-terminal half. These data 
suggest conservation of the RBD fold in alpha-CoV and gamma- or Delta-CoV.  
4.6 Crystal structure of the PRCV RBD bound to the pAPN ectodomain 
The structure of the pAPN crystallized with the PRCV SH3 protein showed a complex of the 
RBD bound to the pAPN ectodomain (Fig. 4.15).  The asymmetric unit of the crystals 
contained two macromolecular RBD-pAPN complexes, with the pAPN ectodomain forming a 
dimer very similar to the others shown in section 4.3.1. On the contrary, the pAPN monomers 
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in the complex had an open conformation, different to the other APN crystal structures (Fig. 
4.10). The PRCV RBD in the structure adopts a β-barrel fold like the TGEV RBD (Section 
4.5). The N and C terminal ends of the RBD and remaining S are distant from pAPN (Fig. 
4.15A), hence unlikely to contact the receptor molecule. Consistent with a cryo-EM structure 
of SARS-CoV S (Beniac et al., 2006), the PRCV RBD also must locate at viral-membrane 
distal region in the S. This should render receptor-binding edge of the CoV S to be accessible 
to the receptor for CoV binding. Each pAPN molecule was engaged by the tip of a single 
PRCV RBD molecule, which bears two exposed aromatic residues (Tyr and Trp) (Fig. 4.15A, 
in red) 
The conformations of the receptor binding loops (β1-β2 and β3-β4) at the tips of the β-barrel 
domains in the structure are identical, suggesting very similar RBD-pAPN interaction in both 
complexes of the asymmetric unit. The virus–receptor interaction buries ~870 Å2 surface of 
the virus protein, 60% of which corresponds to the β1- β2 region (Fig. 4.15B) and 30% to the 
β3-β4 turn (Fig. 4.15C). The pAPN surface buried by the RBD was similar (~770 Å2) and 
included pAPN residues ranging from alpha helix 19 (α19) to 22 (α22) in DIV, and a few 
residues in DII (Fig. 4.8, Table 4.3).  
The structure identified two critical Receptor-Binding Motifs (RBMs) at the pAPN-RBD 
binding interface: 
RBM 1: This motif involved the end of the pAPN helix α19 and helix α21 contacting the β1-
β2 region of the RBD (Fig. 4.15B). The tyrosine side chain (Tyr528 in TGEV) that protrudes 
from the β-turn in the RBD (Fig. 4.15B and Fig. 4.15D), is fully buried in the complex, 
locating between the first N-acetyl glucosamine (NAG7361) linked to pAPN Asn736, the end 
of helix α19, and the first half of the helix α21 (Fig. 4.15B). The hydroxyl group of the RBD 
Tyr528 was found hydrogen bonded to side chains of the pAPN residues Glu731 and Trp737, 
and contributed to virus-receptor binding specificity. The preceding residue, Gly527 of the 
RBD was at the pAPN proximal side of the beta turn, linked by hydrogen bonding to pAPN 
Asn736 main chain. At the opposite side, the RBD Gln530 side chain formed a network of 
hydrogen bonds with pAPN NAG7361 and Asn736 side chain (Fig. 4.15B). The N acetyl 
moiety of the glycan also interacted with the residues at the β2 and β6 strands (Fig. 4.15B, 
Table 4.3). The pAPN N-linked glycan (Asn736) and surrounding residues contacting β1-β2 
region of the RBD in the structure were identified as one of the APN determinants of the 
CoV host range (Tusell et al., 2007).  
 65 
 
A 
 
B 
 
C 
 
D 
 
 
Figure 4.15. Crystal structure of PRCV RBD bound to the pAPN ectodomain. A. Dimeric PRCV RBD-
pAPN complex in the crystals. pAPN molecules are show as ribbons representations with domains (D) in 
orange (N-terminal DI), yellow (DII), red (III) and green (C-terminal DIV) and n-terminal end (n) near the cell 
membrane. The RBD is shown s ribbon and surface drawings in blue and cyan, with the pAPN binding residues 
at the RBD tip in red. Glycans are shown as sticks with carbon in yellow and zinc ion at the pAPN catalytic site 
as a cyan sphere. B. RBM 1. RBD β1–β2 region with the exposed Tyr residue interacting with the pAPN. Side 
chains of RBD and pAPN residues engaged in the interaction are shown as sticks with carbons in magenta or 
green, respectively. NAG7361 glycan N-linked to pAPN Asn736 is shown with carbons in yellow and the 
electron density map, determined without the glycan, shown as a blue mesh contoured at 3 sigma. C. RBM 2. 
RBD β3–β4 region with the Trp residue interacting with the pAPN. D. Structure-based alignment of TGEV and 
PRCV RBD sequences. β-strands are marked with bars. Residue numbered for TGEV. In red, residues 
identified by the structure for 1AF10 mAb- (for TGEV) and pAPN receptor-binding. In B and C, RBD residues 
are numbered following the TGEV sequence shown in D, and intermolecular hydrogen bonds are shown as 
dashed red lines. 
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RBM 2: This region involved a β-turn at the start of the β3- β4 loop in the PRCV RBD (Fig. 
4.15C and Fig. 4.15D). The unique RBD residue Trp571(in TGEV) protrudes at this β-turn 
and docks in a cavity formed by the coils preceding helices 22 (in domain IV) and 5 (in 
domain II) of pAPN (Fig. 4.15C, and Table 4.3). The bulky side chain of this RBD residue 
packed against pAPN residue His786 and Pro787 and its imino group hydrogen bonded with 
the main chain carbonyl group of the pAPN residue Asn783 (Fig. 4.15C).  
Thus, RBD residues Tyr528 as well as Trp571 at the tip of the β-barrel in TGEV and PRCV 
appear to be central residues in the CoV-APN interaction; they contact many pAPN residues 
and contribute also to binding specificities by mediating polar interactions with the pAPN 
(Table 4.3). 
RBD residues pAPN residues 
β1-β2 (RBM1)  
K524/300 T738 
R525/301 T738/Q775 
S526/302 N736/T738/Q775 
G527/303 N736/W737/T738/L768/T771/L772 
Y528/304 G727/E731/N736/W737/Q764/N767/L768/T771/NAG7361 
G529/305 T771 
Q530/306 N736/NAG7361 
P531/307 NAG7361 
I532/308 K735/N736/T738/NAG7361 
A533/309 K735 
S534/310 K735 
T535/311 K735/E739 
L536/312 E739 
β3-β4 (RBM2)  
L570/346 Q775/N782/N783/P784 
W571/347 P366/Q367/S36/N783/P784/I785/H786/P787/R790 
D572/348 Q367 
N573/349 T738 
β5-β6 (RBM3)  
N632/408 NAG7361 
Q634/410 NAG7361 
Table 4.3. Intermolecular contacts in the PRCV RBD-pAPN complex structure. RBD and pAPN residues 
in close contact (≤5 Å) in the two complexes of the crystal asymmetric unit, computed with the program 
NCONT(1994). RBD residues from the β1–β2, β3–β4 and β5–β6 regions at the tip of the β-barrel domain are 
shown, with those engaged in hydrogen bonding in red. TGEV/PRCV numbering is given for the RBD 
residues. 
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4.7 Critical motifs for coronavirus attachment to APN and infection. 
Crystal structures of APN and its complex with the RBD of PRCV defined the CoV-APN 
binding interface and RBM. Based on these crystallographic results we carried out an 
extensive research to identify critical residues for TGEV binding to APN and cell infection.  
4.7.1 Identification of critical TGEV RBD residues for binding to cell surface 
pAPN 
The crystal structure of the PRCV RBD –pAPN complex defined the virus-receptor binding 
interface. Subsequently, we characterized the contribution of residues to the interaction. We 
carried out site directed mutagenesis of RBD residues that contact the APN in the crystal 
structure of the RBD-pAPN complex (Table 4.3).  
 
 
 
Figure 4.16. Binding of TGEV RBD-Fc proteins to pAPN on BHK cells. Binding determined by FACS. 
Plots represent the percentage of cells stained with the wild type and the indicated mutant RBD-Fc proteins for 
a range of protein concentrations. Mean and standard deviation for three experiments. 
 
Mutated residues are in the β1-β2 and β3-β4 loops at the RBD tip, in the nearby β5-β6 loop 
and in the β5-β5b loop of the RBD, which is distant from the pAPN in the structure. 
Mutagenesis was done in the mammalian expression vector pEF/RBD-Fc, which express the 
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TGEV RBD regions fused to the Fc portion of human IgG1 (Materials and Methods). 
Binding of the RBD-Fc protein to cell surface pAPN was done by flow cytometry (FACS) 
with stably transfected BHK-pAPN cells. Binding was determined as percentage of cells 
stained with the wild type and mutant RBD-Fc proteins, using a range of protein 
concentration (Fig. 4.16). Alanine substitution of either the Tyr (Y528) or the Trp (W571) 
residues gave undetectable binding of the RBD-Fc protein at the highest concentration tested, 
which is about 100 times higher than the wild type BC50 (Table 4.4). Similar effect was 
observed only in residues closed to Y528 in the β1-β2 loop, except for the G529D mutation, 
which decreased 80 times the binding activity. Interestingly, mutation of L570, the residue 
preceding W571 in the β3-β4 turn, decreased about 10 times binding.  Substitution of 
residues in the β5-β6 loop, nearby β1-β2 (Fig. 4.15B), also had a mild effect (Table 4.4). As 
expected, residues in the β5-β5b loop, which is distant from the pAPN-binding region in the 
structure of the complex, do not contribute to the interaction (Table 4.4). 
 
4.7.2 Identification of TGEV RBD residues essential for cell infection  
Following the RBD-pAPN binding assays, we determined the role of certain RBD residues in 
TGEV cell entry and infection. Recombinant TGEV (PUR46MAD) mutants were generated 
with mutations in the RBD region of the S, as illustrated before in Figure 3.3. After 
RBD loop RBD-Fc mutant BC50(µg/ml) 
 Wild type 0.318 
β 1-β2  
 
(RBM1 ) 
R525A >30 
G527A >30 
G527D >30 
Y528A >30 
G529D 24.335 
Q530A >30 
I532A >30 
β 3- β4 
(RBM2) 
L570A 4.114 
W571A >30 
β5-β5b V617A 0.423 
V617D 0.257 
β5- β6 
(RBM3) 
T631A 0.230 
N632A 2,442 
TN632AA 4.227 
Q634A 8.235 
NQ634AA 14.855 
   
Table 4.4. Critical TGEV RBD residues for binding to pAPN. RBD-Fc protein concentration staining 
50% (BC50) of BHK-pAPN cells in Figure 4.16 is shown as a measurement of the RBD binding activity. 
The RBD loops where residues locate are shown on the left. 
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confirmation of the mutation by DNA sequencing of the constructs in the pGEM-T vector,  
the mutated S fragments (4.514 kb) were transferred to an intermediate recombinant BAC 
plasmid, pBAC-TGEV
∆claI 
following sequential digestions with PacI and MluI restriction 
enzymes (Fig. 4.17)  This recombinant BAC plasmid contained the cDNA copy of the TGEV 
genomic RNA, except a ClaI fragment (5,198 bp in the TGEV genome, Fig. 3.3) (Almazan et 
al., 2000).  
A 
 
B 
 
C 
 
D 
 
E 
 
  
Figure 4.17. Generation of recombinant TGEV BAC clones with mutations in S. Agarose (0.8%-1%)gel 
electrophoresis. A. Site diercted mutagenesis PCR with (+) or without (-) DNA polymerase of the pGEM-T 
plasmid (P) carrying TGEV S (PUR46MAD). B. EcoRI-XhoI restriction patterns of recombinant pBAC-
TGEV∆ClaI intermediate clones carrying original TGEV genome and mutant spike introduced via PacI-MluI 
transfer. C. Colony PCR based selection of final pBAC-TGEVFL clones carrying ClaI modification from an 
infectious cDNA clone. A 500bp amplicon infers correct orientation of the introduced modification. Analysis 
of genome stability is shown in D and E. D. EcoRI- XhoI restriction patterns of selected clones. E. ClaI insert 
release to confirm the maintainence of this modification in the final clones. Size (bp) of the DNA fragments 
expected from stable clones on the right, whereas the size (Kb) of molecular weight markers (M) on the left.  
 
Stability of the recombinant BAC plasmid was verified by EcoRI-XhoI restriction pattern 
analysis (Fig. 4.17B) and DNA sequencing. In the last cloning step a ClaI fragment from an 
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infectious cDNA clone (pBAC-TGEV
ClaI
) was introduced, resulting in the final construct 
(pBAC-TGEV
FL
) for cell transfection. These procedures were followed for each of the 
intended mutants. Bacterial selection of these final clones is a critical step as their stability is 
highly sensitive to temperatures of bacterial cultures and orientation of the introduced ClaI 
modification. This ClaI modification was found toxic to the bacterial cultures, which 
exhibited a mixture of small and big colonies. As recommended in the established methods 
(Almazan et al., 2008), individual small colonies were selected for each mutant and stored 
frozen.  
Colony PCR confirmed the correct orientation of the ClaI modification in the selected clones 
(Fig.4.17C). Low incubation temperature (30
o
C) was used during bacterial amplification of 
selected final BAC preparations to minimize toxicity issues. EcoRI-XhoI restriction patterns 
verified the stability (Fig. 4.17D) and ClaI restriction proved the presence of the introduced 
modification in the pBAC-TGEV
FL 
(Fig. 4.17E). Large Construct kit method (Qiagen) 
facilitated the extraction of pure, genomic DNA free pBAC-TGEV
FL
 preparations. 
Monolayer of BHK-pAPN cells were transfected with at least 4 µg of pBAC-TGEV
FL
 for 
each construct (wt and mutants) using Lipofectamine-2000 (Invitrogen). After 6 hours, these 
cells were overlaid on fresh ST cell monolayer following brief trypsinyzation. In parallel, 
another set of transfection was done to visualize cytopathic effects on BHK21-pAPN 
monolayers. Supernatants were collected two days after transfection and used to infect ST 
cell monolayers for their titrations following standard plaque forming assays (Fig. 4.18A). 
Infectious virus units were determined for wild type and TGEV mutants (Fig. 4.18B). 
Five TGEV mutants show lack or negligible cell infection, and include mutations in β1-β2 
(G527D and Y528A at RBM1), β3-β4 (W571A at RBM2) and into the β5-β6 regions that 
contact RBM1 and the pAPN NAG (Fig. 4.15). Tyr528 appears the most critical APN-
binding residue and no plaques have been observed for deletion of its side chain.  
Nonetheless, W571 is also a key APN-binding residue for TGEV as infectivity of the W571A 
mutant gave 8 log decrease in infectivity.  We do not fully understand the large effect 
observed with the N632A and the NQ634AA, which did not give a very significant decrease 
in RBD binding to APN (Table 4.4). They could affect conformation of RBM1, but further 
experiments are required to confirm its involvement in TGEV infection. The other mutations 
had a lower effect (1-3 log) on TGEV cell infection, even those belonging to RBM1 affected 
significantly RBD binding to APN (Table 4.4). Among those residues Gln530 and Ile532 
appear to contribute more than the others, even though they are not required for virus entry 
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and infection, as Tyr528. Interestingly, the G529D mutant was infectious, as previously 
shown for a TGEV mutant that escape to mAb neutralization (Gebauer et al., 1991, Delmas et 
al., 1990).  
A 
 
B 
 
 
Figure 4.18. Cell infectivity profiling of the TGEV mutants. A. Supernatants from BHK-pAPN cell 
monolayers, transfected with BAC plasmid preparations of TGEV genome (pBAC-TGEVFL) carrying 
structure guided mutations in TGEV S, were used in virus titration. ST cell monolayers seeded in 24 well 
tissue culture plates were inoculated serially with tenfold dilution of the virus stocks and plaques were 
counted by crystal violet staining (Section 3.10). B. Plaque forming assays (A) quantified virus tire 
(log10Pfu/ml) in virus stocks of wt and mutants. RBD residues in which mutations locate are shown at the 
bottom. 
 72 
 
4.7.3 An N-linked glycosylation in the pAPN ectodomain that is essential for 
PRCV RBD binding 
In the PRCV RBD-pAPN crystal structure, the pAPN Asn 736 and the linked NAG 
carbohydrate bury the RBD Tyr528 and form a network of hydrogen bonds with residues in 
the RBD β1-β2 loop (Fig. 4.15, Table 4.3). To test the contribution of this N-linked glycan to 
pAPN DIV, we engineered two pAPN mutants lacking the glycosylation (N736A and 
T738V). We expressed membrane bound wild type and glycosylation pAPN mutants, and 
analyzed binding of RBD-Fc to these pAPN mutants. Flow cytometry data indicated 
negligible RBD binding of the glycosylation pAPN mutants (Fig. 4.19).  
 
 
 
Figure 4.19. RBD binding to cell surface pAPN glycosylation mutants. Relative binding of the RBD-Fc 
protein and the anti-HA mAb to HA-tagged pAPN proteins with (pAPN) or without the glycan linked to 
Asn736 (N736A and T738V). ). HA binding measures amount of cell surface protein. Mean and standard 
deviation for three experiments.  
 
This is consistent with the findings on homologous glycan in feline APN (Tusell et al., 2007); 
its deletion similarly prevented cell infection by feline, canine and porcine CoV, all of which 
share the glycan-binding (Tyr528) residue (Fig. 4.14) at the β1-β2 turn (Fig. 4.15). Moreover, 
introduction of this glycan to human APN is known to sufficiently renders it a TGEV 
receptor (Tusell et al., 2007). 
4.8 APN ectodomain dynamics in CoV binding 
4.8.1 The TGEV RBD specifically recognizes the open pAPN ectodomain 
The porcine CoV RBD binds to a pAPN ectodomains with the most open conformation 
reported for mammalian APN (Fig.4.11)(Reguera et al., 2012). The CoV-binding region is 
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distant from the catalytic site, on the opposite side of the ectodomain (Fig. 4.15). A critical 
APN-binding motif with a tryptophan in the CoV RBD penetrates a narrow cavity formed by 
DII and DIV (Fig. 4.20). Tryptophan aromatic side chain stacks onto pAPN DIV residues 
His786-Pro787, and is trapped by DIV residue Asn783-Pro784 on one side and DII residues 
Pro366-Gln367 on the other (Fig. 4.20). The main chain of DII residues is in close contact 
(3.9Å) with the tryptophan side chain, and its imino nitrogen forms a hydrogen bond with the 
Asn783 carbonyl. DIV-based superposition of the structure of open pAPN with bound RBD 
and that of closed pAPN showed a shift in the DII main chain region that contacts the RBD, 
this region collides (<3.0 Å) with the CoV tryptophan bound to the open APN (Fig. 4.20). 
Closing of the ectodomain would thus hinder penetration of the viral tryptophan between the 
pAPN DII and DIV domains.  
 
 
 
Figure 4.20. Conformation of the CoV binding cavity at the DII-DIV interface in the open and closed 
pAPN structures. Structures were superposed based on DIV. Ribbon diagrams of the open pAPN in 
complex with the porcine CoV RBD, with residues that contact the RBD in sticks with carbons in yellow 
(DII) and green (DIV). The same residues are shown for the superposed closed structure with carbons in 
grey. The RBD motif that penetrates the pAPN cavity is shown with a grey surface and residues in sticks 
with carbons in cyan or magenta (Trp). Nitrogens in blue and oxygens in red. 
 
4.8.2 Drugs that bind the catalytic site inhibit TGEV RBD binding to pAPN 
Metalloprotease inhibitors are mostly nonhydrolyzable drugs that act by binding the catalytic 
site. These ligands appear to restrict APN ectodomain movement, as shown by the reduction 
in number of APN conformation-specific mAb epitopes (Xu et al., 1997). Also, crystals of 
M1 aminopeptidases in complex with these drugs exhibit preferential closed state (Addlagatta 
et al., 2006, Kochan et al., 2011, Nguyen et al., 2011). Thus, these ligands would not only 
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compete with substrate for binding to the active site, but may also restrict aminopeptidase 
dynamics, a requisite for peptide hydrolysis and release.  
CoV binding depends on APN dynamics and transition to an open conformation (Fig. 4.20). 
Restricted APN dynamics by active site-binding inhibitor ligands would favor an allosteric 
effect on CoV binding. To verify this hypothesis, the outcome of active site inhibitor drugs 
on TGEV RBD binding to cell surface expressed pAPN was studied (Fig. 4.21). In flow 
cytometry, binding of RBD-Fc fusion protein to pAPN expressing BHK cells alone or in 
presence of actinonin and/or bestatin was analysed (Fig. 4.21A). Both the drugs blocked 
RBD-Fc binding to APN and effect was found concentration-dependent (Fig. 4.21B). 
Actinonin has higher affinity for APN (IC50 ~1µM) than bestatin (IC50 ~20µM) and 
consequently inhibited RBD binding more effectively. 
A 
 
B 
 
C 
 
D 
 
Figure 4.21. Effect of APN catalytic inhibitors on CoV RBD binding to the receptor. A. Flow cytometry 
monitoring binding of the RBD-Fc protein (1 g/ml) to BHK-pAPN cells is shown as continuous line 
histograms on the left. Discontinuous histogram corresponds to an unrelated Fc fusion protein. The vertical 
dot line marks the threshold fluorescence to compute the percentage of stained cells with the RBD-Fc protein. 
On the right, overlay plot of histograms obtained with 1 g/ml RBD-Fc in the absence (white) or presence of 
500 M bestatin (grey) or actinonin (black). B. Relative RBD-Fc binding to BHK-pAPN cells in the absence 
and presence of increasing concentration of bestatin and actinonin. Percentage of positive cells computed by 
flow cytometry was used to calculate the plotted ratios. Mean and standard deviation of three experiments. C. 
Relative RBD-Fc binding to 293T cells expressing wild type and catalytic mutant pAPN proteins. Binding 
was computed as in panel B with cell expressing similar amount of cell surface proteins, with (1 mM) and 
without drugs. D. RBD-Fc binding to CHOK1 cells expressing similar amounts of wild type (wt) and/or 
catalytically inactive HH/AA mutant in flow cytometry as in A. 
 
To determine whether this is an allosteric effect of drug binding to the active site distant from 
the CoV-binding region, binding of RBD-Fc to two catalytically inactive pAPN mutants was 
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analyzed on surface of 293T cells, alone or at higher concentrations of both the drugs. Both 
drugs inhibited RBD-Fc binding to pAPN, although the effect in 293T was less pronounced 
than that in stably expressing BHK-pAPN cell. The drugs did not inhibit RBD-Fc binding to 
pAPN catalytic mutants (Fig. 4.21C). Besides, CHOK1 cells stably expressing catalytically 
defective pAPN mutant (Fig. 4.21D) do not show any inhibition of RBD-Fc binding under 
drug treatment. These results prove that active site binding drugs cause allosteric inhibition of 
TGEV RBD binding to pAPN, probably by restricting APN ectodomain opening.  
4.8.3 Allosteric inhibition of pAPN catalysis by the TGEV RBD 
CoV binds to the open APN and the structure data indicate it might lock the ectoenzyme in its 
open conformation (Fig 4.20). This would prevent the movements required for substrate entry 
and release during hydrolysis (Fig.4.20). To verify this hypothesis, the catalytic activity of 
soluble human and pig APN ectodomains was studied (Fig. 4.22) in presence of pig CoV 
spike fragments bearing the RBD (shown in Materials and Methods, Fig. 3.2).  
A 
 
B 
 
 
C 
 
 
Figure 4.22. Allosteric inhibition of APN catalysis by CoV S proteins. APN catalysis was monitored for 
soluble hAPN and pAPN ectodomains by measuring the change in optical density (OD405nm) from LpNA 
catalysis (Materials and Methods, Section 3.8). A. Activity determined for pAPN and hAPN (0.04 µM) 
alone or in the presence of the indicated porcine S proteins (10 µM), which specifically bind to 
pAPN(Reguera et al., 2011). An unrelated PVR-Fc fusion protein was used as control. B. Activity 
determined with increasing RBD/APN molar ratios. C. Inhibition of pAPN catalytic activity by the TGEV 
RBD with time.  
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The soluble spike proteins specifically inhibited pAPN catalysis, while hAPN catalysis was 
not affected (Fig. 4.22A). The TGEV RBD fragment was sufficient to inhibit catalysis of 
pAPN. Inhibition was directly dependent on RBD concentration and a high RBD/pAPN ratio 
was needed to achieve maximum catalytic inhibition (60%, Fig. 4.22B), which decreased 
slowly after 40 mins (Fig. 4.22C), probably due to slow RBD release from pAPN. The RBD 
thus can specifically prevent catalysis in only a fraction of APN molecules. These APN 
molecules are probably in open conformation as the catalytically active APN (closed) 
molecules would not allow RBD binding. The results suggest that the open APN is 
catalytically inactive and that blocking APN dynamics prevent catalysis. 
4.9 Mutations in the pAPN catalytic site affect TGEV cell infection 
The effect of APN enzymatic activity on CoV infection has not been studied in detail. A 
report with one TGEV strain shows lack of effect with transient transfected HEK239T cells, 
in experiments where the pAPN cell surface expression were not properly monitored for wild 
type and catalytically inactive mutants (Delmas et al., 1994). We have analyzed TGEV 
infection of CHOK1 cells expressing similar amounts of wild type and catalytically inactive 
pAPN on the cell surface.  
Two sets of cell clones expressing similar amounts of wild type and the pAPN HH/AA 
catalytic mutant were selected by flow cytometry, based on similar RBD-Fc binding (not 
shown). The pAPN-HH/AA mutant lacks the histidine residues that coordinate the zinc atom 
at the active site (Fig. 4.12). The lack of enzymatic activity of this mutant in CHO cells was 
verified using the L-pNA substrate in the cell monolayers (Fig. 4.23A and B). TGEV 
(PUR46MAD) and PRCV (HOL87) were used to infect cell monolayer on 96 well plates at 
various dilutions and the cytopathic effect was determined (Fig. 4.23C and D). TGEV 
infectivity of CHO cells expressing the pAPN-HH/AA mutant was reduced (2.5 log) with 
respect to cell expressing wild type pAPN, whereas PRCV equally infected both cell types. 
The pAPN enzymatic activity can thus be important for cell infection by certain TGEV 
strains.  
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Figure 4.23. APN enzymatic activity and CoV infection. A. ELISA test monitoring the enzymatic activity 
of CHOK1 cells expressing wild type (WT) and the pAPN-HH/AA mutant (Materials and Methods, section 
3.8). Two different pairs of WT and mutant pAPN clones (1 and 2) having similar cell surface expression are 
shown. Wells with untransfected CHOK1 cells included as control. B. OD405nm of samples shown in A C. 
Cytopathic effect (CPE) of TGEV (PUR46MAD) and PRCV (HOL87) infection of the CHOK1 cells 
monolayers described in A. Virus stock dilutions are shown on the top. D. TCID50 determined for CPE in C. 
Infectivity was monitored as OD620nm, and dilution corresponding to 50% cell infection determined as 50% 
reduction of OD of uninfected cells.  
 
4.10 The pAPN-binding region of the TGEV spike is the main 
determinant of antigenic site A 
Monoclonal antibodies (mAb) that neutralize TGEV infections are known to recognize 
antigenic site A in the TGEV S (Fig. 3.2B), which has been mapped to the RBD (Gebauer et 
al., 1991, Sune et al., 1990, Delmas et al., 1990). Sites A includes overlapping but distinct 
epitopes of several neutralizing mAb, and it was divided into subsites Aa, Ab, and Ac 
(Gebauer et al., 1991). Previous work by the group showed that a mAb that belongs to site A, 
1AF10, recognize the RBD tip (PDB code 4F2M) (Reguera et al., 2012). 
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Figure 4.24.Identification of determinants of TGEV S antigenic site A. Normalized binding (%) of site 
A-specific mAbs to RBD mutants. mAb representative of the three A subsites were analyzed. HA mAb was 
used as a control. RBD regions in which mutations locate are shown (bottom). 
 
To characterize further antigenic site A and epitopes of other TGEV neutralizing Ab, we 
analyzed by ELISA binding of several antigenic site A-specific mAbs to RBD mutants. 
Substitutions of pAPN-binding residues, G527D, Y528A and G529A in the RBM1 of the 
TGEV RBD (Fig. 4.15) abolished binding to Ac subsite-specific mAbs, 1AF10 and 6AC3 
(Fig. 4.24). The Y528A mutant bound subsite Aa- (1BB1) and Ab (1DE7) specific mAbs and 
G529D mutant also recognized mAbs 1DE7. On the other hand, mutation of the other key 
receptor binding residue in RBM2 (Table 4.3, Fig. 4.15C), W571 did not affect RBD binding 
to the Ac subsite specific antibody, but that to Aa and Ab subsite antibodies was greatly 
reduced (Fig. 4.24).Mutations of three residues at the β3-β4 turn (LWD572A mutant) in the 
RBM2, greatly reduced its binding to 6AC3 mAb with only partial reduction in 1AF10 
binding (Fig. 4.24). This infers that mAb 6AC3 recognizes a broader epitope, which thereby 
is responsible for its higher TGEV neutralization activity (Sune et al., 1990). Mutation in 
residues forming the β5-β6 hairpin (T631 and N632), which is close to the β1-β2 loop 
(RBM1), reduced binding with all site A specific antibody. This broad effect could be 
accounted for a conformational effect induced at the essential receptor-binding β1-β2 region. 
Results from antibody binding assays with RBD mutants infer that site A epitopes encompass 
the RBD tip region, although some differences exist among the three a subsites. The RBD 
epitopes recognized by Aa-and Ab-subsite specific mAbs bear the exposed W571 residue at 
the β3-β4 loop (RBM2), whereas the epitopes for the Ac-specific mAbs center on Y528 in the 
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β1-β2 turn (RBM1). None of the tested mAbs simultaneously targeted the two aromatic side 
chains (Y528 and W571) at the tip of the RBD that bind pAPN (Fig. 4.15). Nonetheless, 
binding to a single RBM is sufficient to prevent TGEV binding to APN and neutralize 
infectivity
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5. DISCUSSIONS 
The work presented here delivers compelling structural view of the APN ectodomain; it 
reveals its architecture, dynamic conformation, and provides new insights on its multiple 
functions related to peptide catalysis and CoV cell entry. APN is a major CoV receptor and 
one of the three metalloproteases that this virus family uses to attach to the host. We show 
how CoV attaches to the cell surface APN and the way CoV neutralizing antibodies prevent 
infection by inhibition of CoV-APN binding. 
5.1 Mammalian expression system for structural biology of membrane 
protein  
X-ray crystallography requires relatively large quantities of proteins for crystallization; 
glycoproteins must be produced using mammalian cell based expression systems (Aricescu et 
al., 2006). They have proved very effective, especially for the production and crystallization 
of secreted soluble glycoproteins (Jones et al., 1992, Ordono et al., 2006, Casasnovas et al., 
1997, Wu et al., 1997). Accordingly, work in this Thesis was founded upon preliminary 
transient expression of proteins of interest into HEK-293T cells which verified their 
expression and correct folding using biochemical and immuno-assays. CHOLec 3.2.8.1 was 
the best suited cell line for the large scale production of proteins, due to the low complexity 
of glycosylation from this cell line ensured by a defective glycosylation pathway (Chang et 
al., 2007). The proteins secreted from stable CHOLec cell clones exhibit simple high 
mannose chains with only two N-acetyl glucosamine (NAG) and five mannose residues. This 
renders their easy deglycosylation by Endo-H, which leaves only a single NAG residue in the 
glycoprotein linked to the Asn residues and preserves glycoprotein conformation. 
High expression level in CHOLec cell clones was achieved with the glutamine synthetase 
(GS) system, based on a vector that includes the GS and the gene of interest. Expression is 
done under glutamine starvation in presence of the methionine sulfoximine (MSX), a GS 
inhibitor that induces gene amplification and increases protein expression. Besides the large-
scale production, the next important hurdle is the purity of the protein of interest due to its 
low abundance in the mammalian cell supernatants which also contain serum proteins. This 
was taken care by and affinity purification step from cell supernatants (Ordono et al., 2006) 
which gave a fairly pure protein in high yields to further downstream purification and use in 
crystallization screening trials.  
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5.2 Structural features of Aminopeptidase N (APN)  
The presented crystal structures of APN depicted a domain architecture resembling that of 
related aminopeptidases (Kochan et al., 2011, Nguyen et al., 2011, Addlagatta et al., 2006), 
although the APN ectodomain is heavily glycosylated and forms dimers. DI, DII and DIII are 
more similar to homologous domains in M1 aminopeptidases than DIV. Human and pig APN 
domain structures are very similar, except for the DIV ARM repeat, which contains a highly 
flexible region whose conformation varies among APN structures. The APN ectodomain can 
adopt different conformations, related to interdomain movements. This inherent 
conformational dynamics determine APN multiple functions related to peptide hydrolysis and 
CoV cell entry (Fig. 5.1).  
Mammalian APN are known to exist as stable dimers on the cell surface (Hussain et al., 
1981). The dimeric APN state may enhance protein stability in extracellular environments. 
Dimerization was also found in soluble ectodomain prepared for crystallization. Different 
crystal structures exhibited this unique homodimerization in APN ectodomains mediated by a 
large DIV surface in contacting monomers. Introduction of a glycosylation motif at the 
dimerization interface disrupted dimerization both in soluble and cell surface forms of the 
pAPN. These results supported the involvement of domain IV in dimerization proving the 
relevance of the crystal structure dimers. This APN dimer is unique among M1 
aminopeptidases (Kochan et al., 2011, Nguyen et al., 2011, Addlagatta et al., 2006), which is 
likely related to the distinct DIV conformation and sequence in APN. The DIV-„bowl‟ 
exhibits a pore in its  bottom and it has been proposed as an entry point to small peptide 
substrates to access the catalytic center in other aminopeptidases (Addlagatta et al., 
2006).This pore is plugged by APN dimerization, preventing its use in substrate entry to the 
active site. 
In the structures, the APN monomers appear tilted in the dimer, but their N-termini point to 
the center of the dimer, likely locating nearby the transmembrane domains of the two 
monomers. Cell signaling feature of APN (Mina-Osorio, 2008) can be attributed to the 
organization of its membrane proximal regions and transmembrane segments and interaction 
of these domains with other cell surface proteins. These features can be influenced by APN 
ectodomain movements. 
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Figure 5.1. APN conformations and functions on the cell surface. The diagram discusses the prevalence of 
two conformational states of APN on the host cell surface. Substrate entry, locking and cleavage are favored by 
the catalytically active (closed) conformation while the inactive (open) conformation facilitates product release. 
Both the conformations are shown to exist in dynamic equilibrium. 
 
5.2.1 The dynamic structure of mammalian APN 
We have determined several APN dimeric crystal structures that show different 
conformational states of the ectodomains.  This conformation dynamics is an intrinsic 
property of aminopeptidases, and it has been also described in ectoenzymes used as CoV 
receptors. The APN ectodomain movements are less pronounced and differ from that 
reported for other M1 aminopeptidases. These differences could be due to the APN dimeric 
conformation and its linkage to the cell surface. Dimerization only engages the DIV region, 
and we found that the dimer is preserved in closed, intermediate and open APN structures. 
APN DIV is locked by dimerization and thus cannot move as described for ERAP-1 or F3 
(Kochan et al., 2011, Kyrieleis et al., 2005), proteins that do not exhibit dimerization. The 
fixed conformation of the APN dimer determines that the DI-DII-DIII module swings over 
DIV, with the hinge at the DIII C terminus at the beginning of DIV. Moreover, the swing 
angle is less prominent in APN (15
º
) than in its closely related ERAP-1 (22
º
), despite very 
similar closed state conformations.  Displacement of the DI-DII-DIII APN module must be 
limited by the length of the flexible polypeptide that links DI to the transmembrane region, 
whose movement is restricted by membrane fluidity. Dimerization and linkage to the cell 
surface could be two important determinants of the APN dynamics described here. The extent 
of APN movement nonetheless appears to be sufficient for the release of the hydrolyzed N-
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terminal residue, which is distant from DIV in the open or in the intermediate APN 
conformations. It is not clear the way each monomer in the dimer moves, whether their 
movement is random or synchronized, in the same or inverse directions. Experiments with 
monoclonal antibodies (Xu et al., 1997) and those shown here with the TGEV RBD (Fig. 
4.21) suggest that ~50% of the molecules adopt different conformations;  these data imply 
that APN monomer adopts a distinct conformation and its movement is probably 
independent. 
The crystal structures reported here not only provide snapshots of APN dynamic 
conformation, but also guide experiments to confirm its importance in the functions of this 
aminopeptidase. APN exhibited open, intermediate, and closed conformations in the various 
structures presented here. The transition between a proteolytic active (closed) and an inactive 
(open) forms has been proposed important for the function of several M1 aminopeptidases 
(Kyrieleis et al., 2005, Kochan et al., 2011, Nguyen et al., 2011, Addlagatta et al., 2006). This 
dynamics is thought to be required for peptide hydrolysis and release from the 
aminopeptidase active site. The different APN structures do not show any change on the 
conformation of active site residues in DII (Fig. 4.12A), but they have significant differences 
in contacts between DII and DIV residues. The region that joins 26 and 27 in the DIV 
ARM repeat penetrates the active site groove in closed APN structures (Fig 4.12B).  
After APN closure, a conserved phenylalanine in this region locks the substrate coordinated 
to the zinc ion, permitting hydrolysis. Further processing of the peptide requires removal of 
the phenylalanine “lock” by opening the APN ectodomain, facilitating N-terminal residue 
release and peptide translocation, both sterically hindered in the closed conformation.  The 
inherent flexibility in the DIV ARM repeat might also enable substrate processing during 
catalysis. 
5.2.2 APN dynamics and allostery 
Studies towards realizing the effect of APN catalytic inhibitors on TGEV RBD-pAPN 
interaction and subsequent analysis of CoV S proteins on APN catalysis identified allosteric 
effects, likely related to restrictions in ectodomain movements (Fig. 5.2). Catalytic sites and 
CoV binding regions are quite distant in ectoenzymes serving as entry receptors (Li et al., 
2005a, Wu et al., 2009, Reguera et al., 2012, Chen et al., 2013) and the respective functions 
are believed to be independent of each other (Delmas et al., 1994, Moore et al., 2004). 
Contrary to this notion, studies presented in this Thesis show that in APN agents that bind to 
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one region do prevent activities linked to the other. As mentioned above, the switch between 
an active (closed) and an inactive (open) form has been proposed essential for peptide 
hydrolysis in M1 aminopeptidases (Kyrieleis et al., 2005, Kochan et al., 2011, Nguyen et al., 
2011, Addlagatta et al., 2006), but never demonstrated. Using different APN ligands that bind 
to distinct sites, we carried out several experiments to determine the functional relevance of 
the different APN conformations and its conformational switch. We show that binding of 
TGEV S proteins to open APN blocks catalysis, thus confirming the crucial role of APN 
dynamics in catalysis and demonstrating that the open APN structure is inactive in peptide 
hydrolysis. 
 
 
Figure 5.2. APN dynamics and allostery. Cartoons show APN with two functionally distinct 
conformational states. The open conformation is specifically recognized by CoV, whereas substrate 
hydrolysis must occur in the closed APN. The allosteric inhibition of APN functions shown here using viral 
proteins and drugs must be due to suppression of APN transient conformational states. 
 
Drugs that bind to the active site promote closing of aminopeptidases (Addlagatta et al., 
2006, Kochan et al., 2011, Nguyen et al., 2011), and they can thus be used to test its influence 
on CoV binding, which needs APN to open. These drugs inhibited binding of porcine CoV 
proteins to pAPN, probably by preventing opening of the ectodomain. The allosteric effects 
shown here with different ligands must be due to suppression of APN transient 
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conformational states (Fig. 5.2), such as that recently suggested by NMR studies of enzymes 
(Tzeng and Kalodimos, 2013). Blocking APN motions can prevent APN functions, and 
suggests a new approach for the development of drugs that target this protein.  Inhibitors of 
ectodomain movements can bind to the active site, or interact with distant sites, such as 
shown here with the TGEV RBD fragment. 
We have related two APN functions with different protein structures. APN peptide hydrolysis 
requires ectodomain closing as well as some opening for peptide release, whereas CoV 
specifically recognize the open APN conformation. These results show that the dynamic 
conformation of the APN ectodomain determines its multiple functions. 
5.3 The CoV-APN interaction 
The CoV S is a multifunctional glycoproteins that mediates both CoV attachment to cell 
surface molecules and membrane penetration by fusion. The N-terminal S1 region contains 
several domains that recognize cell entry receptors. In most CoV, the major determinants of 
cell tropism are found in the C-terminal portion of the S1 region (Masters, 2006, Gallagher 
and Buchmeier, 2001). These RBD have structures that are unrelated to host proteins, and 
they can thus be considered genuine CoV RBD. They recognize the APN, ACE2 or DDP4 
ectoenzymes. APN is a cell entry receptor for most alpha-CoV. Our research showed how a 
group of CoV attaches to the cell surface APN metalloprotease for entry into host cells, and 
the way some CoV-neutralizing antibodies prevent infection. These studies are relevant for 
understanding receptor recognition in CoV, its evolution and the adaptation of this virus 
family to different hosts.  
The RBD of porcine and related alpha-CoV adopt a similar β-barrel fold, with some 
structural divergences in its receptor-binding tip (Fig. 4.14). The RBD of CoV that bind APN 
have a tip with protruding receptor-binding motifs, which engage recessed surfaces on a 
membrane distal region of the receptor. PRCV and TGEV contain two main RBM, each 
composed by a loop that bears an exposed aromatic residue, tyrosine or tryptophan. RBM1 
(β1-β2 region) has a tyrosine and it contacts with an α-helix and an N-linked glycan in the 
APN ectodomain. The inherent flexibility of this glycan might facilitate the initial contact of 
the CoV tyrosine with APN amino acids, and subsequent virus-receptor interactions could 
lock the bound Tyr between the glycan and an α-helix. Besides the tyrosine, other RBD 
residues contact the APN and they establish a network of interactions with the APN, 
including the N-linked NAG. The β5-β6 region at the RBD tip contact also with the glycan, 
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and it appears to stabilize the protruding conformation of the APN-binding β1-β2 loop. 
RBM2 at the beginning of the RBD β3-β4 loop contains a tryptophan residue that penetrates 
in a narrow cavity formed by the APN DII and DIV. The β3-β4 loop preserves the tryptophan 
in all the APN-binding CoV, in the alpha1-group and even in HCoV-229E, which has an 
RBD with a shorter loop (Fig. 4.14). This contact is responsible of the specific CoV binding 
to the open APN, which can accommodate the large tryptophan side chain. Other residues in 
RBM2 contact the APN in the crystal structure of the porcine RBD-pAPN complex, however 
they do not appear essential for either CoV S protein binding to APN or cell infection. In 
contrast, residues surrounding the tyrosine in RBM1 are also important for S protein binding 
to the APN, indicating that RBM1 could be a higher contribution than RBM2 to the stability 
of the CoV-APN interaction. 
Receptor glycosylations are important determinants of CoV-receptor recognitions. They can 
favor or hinder CoV binding to cell entry receptors in certain species (Li et al., 2005a, Tusell 
et al., 2007), delimiting the CoV host range. A glycan linked to rat ACE2 Asn82 prevents its 
use as an efficient SARS-CoV receptor (Li et al., 2005a). Addition of an N-linked glycan to 
the human APN converts it into a TGEV entry receptor (Tusell et al., 2007). We show here 
that TGEV and PRCV specifically recognize an N-linked APN glycan. This glycan N-linked 
to amino acid Asn736 in pAPN is also conserved in canine and feline APN, as are the viral S 
protein residues that interact with this glycan in RBM1 (β1-β2 loop). This unique glycan-
virus interaction must thus be conserved among the members of the species alpha1-CoV, in 
accordance with the glycan requirement reported for cell infection by CCoV, FCoV, and 
TGEV (Tusell et al., 2007). The lack of this glycan in human APN and the absence of the 
interacting Tyr residue in the β1–β2 region of HCoV-229E RBD (Fig. 4.8 and Fig. 4.14) 
imply distinct virus-APN local contacts in humans. Recent crystal structures show that the 
MERS-CoV RBD also bind to a glycan N-linked to DPPIV (Wang et al., 2013). Even though 
structures of MERS- and alpha-CoV RBD are very different, they both recognize N-linked 
glycosylations, showing this is a common feature and a unique characteristic of CoV-receptor 
interactions. 
5.4 Conformation of the receptor-binding regions determine receptor-
specificity in CoV  
CoV RBD folding, conformation of the receptor binding motifs and subtle changes in these 
motifs determine receptor binding specificity and CoV host range. Alpha- and beta-CoV 
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RBD adopt two distinct folds, and they bind to different ectoenzymes. The alpha-CoV RBD 
have a β-barrel fold, whereas the RBD of the SARS- and MERS-CoV (beta-CoV) assumes a 
very different conformation (Li et al., 2005a, Chen et al., 2013). They are composed of two 
subdomains, the core and the receptor-binding subdomain, and both contain a single β-sheet.  
Even though alpha- and beta-CoV RBD are very different structurally, the HCoV-NL63 
(alpha-CoV) and the SARS-CoV bind to the same protein, ACE2. The mode these CoV bind 
ACE2 shares similarities; they recognize overlapping ACE2 regions, including two helices 
and a unique -turn in the virus-binding lobe of the receptor (Wu et al., 2009) (Li et al., 
2005a). The ACE2-binding surfaces in both CoV are concave and exposed distant from the 
terminal end of the RBD. Virus use of recessed surfaces to bind to exposed receptor motifs is 
a strategy to hide conserved receptor-binding residues from antibodies (Casasnovas, 2013, 
Rossmann, 1989). These two CoV have highly distinct RBD, but their receptor-binding 
region evolved to recognize the same receptor molecule. HCoV-NL63 and PRCV/TGEV 
RBD have a similar β-barrel fold, but they use different entry receptors, ACE2 and APN, 
respectively. 
The structures of PRCV RBD-APN (Fig. 4.15) and HCoV-NL63 RBD-ACE2 (Wu et al., 
2009) complexes show reversed modes of CoV-receptor recognition, and identified the basis 
for the different receptor-binding specificity among alpha-CoV (Fig. 5.3). PRCV, TGEV and 
alpha1-CoV S bear RBD with bidentate and protruding tips that can penetrate in small 
cavities of the APN ectodomain; on the contrary, the HCoV-NL63 RBD tip has a “bowl”-like 
tip that cannot bind to APN, but recognizes exposed ACE2 motifs, following a similar 
receptor-binding strategy to beta-CoV. The conformation of the RBD tip thus dictates the 
receptor molecule alpha-CoV recognize (Fig. 5.3). 
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Figure 5.3. Conformation of receptor-binding regions in the RBD of alpha-CoV, a determinant of its 
receptor-binding specificity. Ribbon diagram of the PRCV (left) and hCoV-NL63 RBD (right) structures 
determined in complex with the APN (Fig. 4.15) and ACE2 (NL63, PDB ID 3KBH) (Wu et al., 2009), 
respectively. Receptor-binding surfaces in the RBD are shown in pink or red (tyrosine or tryptophan 
residues) and were generated by the RBD residues that contact the respective receptor molecules in the 
structures. 
 
5.5 Immune neutralization of CoV TGEV and related alpha-CoV 
Site A in the TGEV S is recognized by potent TGEV neutralizing mAb.  In this Thesis we 
show that epitopes of several neutralizing mAb overlap with the receptor-binding region in 
the RBD, showing that the RBD tip is the major antigenic determinant in the envelope S 
protein of CoV that bind APN.  All TGEV neutralizing mAb tested recognize TGEV residues 
that bind to APN; mAb bind either to the tyrosine or the tryptophan exposed in the RBD tip.  
The most potent mAb, 6AC3, targets the tyrosine, which we showed here as a key residue for 
TGEV binding to APN and infection. 
The identification of the RBD tip as a major antigenic determinant in the TGEV S, 
demonstrate that the receptor-binding region in Alphacoronavirus is under selective pressure 
from the immune system. It is tempting to speculate that immune pressure on exposed 
receptor-binding residues in the CoV S could lead to conformational changes in receptor-
binding edges of CoV RBD. This would result either in changes in the APN-recognition 
mode reported for HCoV-229E (Tusell et al., 2007), or important conformational changes in 
the RBD tip that lead to a receptor specificity switch for cell entry, as in HCoV-NL63 (Fig. 
5.3). These data on CoV indicates that the humoral immune response can drive evolution of 
receptor recognition in viruses.  Moreover, the identification of antigenic site determinants in 
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the alpha-CoV S protein, could guide the design of immunogens that boost immunity towards 
critical motifs for virus cell entry. 
5.6 CoV selection of ectoenzymes as cell entry receptors 
Alpha- and beta-CoV S glycoproteins contain RBD with distinct and unique folds, which are 
thought to have evolved from a common CoV RBD ancestor. They share an important 
common feature, the recognition of ectoenzymes. Some of these enzyme features must be 
essential for CoV entry into host cells.  CoV preferential selection of ectoenzymes as cell 
entry receptors is unclear. It might be linked to their abundance on epithelial cells rather than 
on their peptidase function, which does not appear to be essential for CoV cell entry (Li et al., 
2005b). Perhaps they cluster with other proteases that facilitate fusion (Glowacka et al., 
2011). Here we analyzed porcine CoV infectivity in CHO cell clones expressing similar cell 
surface amounts of wild type and a catalytic mutant pAPN. Preliminary results included in 
this Thesis indicate decreased TGEV infection of cells expressing the catalytically inactive 
pAPN. This effect was strain specific and no effect on cell infectivity was observed on PRCV 
infection. PRCV is also known to form syncytia on cell monolayers; virus spreading by cell-
cell fusion may not require APN enzyme activity. The differences may be also responsible of 
the distinct PRCV and TGEV tropism. Nonetheless, further studies are required to evaluate 
APN activity on CoV cell infection. The three cell surface CoV receptors described to date, 
ACE2, APN and DPP4, have distinct structures and functions, but their ectodomains share an 
inherent conformational flexibility (Xu et al., 1997, Boonacker and Van Noorden, 2003, 
Towler et al., 2004) that could assist in dissociation of the S1-S2 heterotrimer during cell 
entry.  Trimeric spikes that bind simultaneously to several receptor molecules could 
disassemble by pulling forces generated during ectodomain movement. The conformation 
and dynamics of the APN ectodomain vary with the pH (Table 4.2), so that endosomal 
acidification can alter APN conformation during receptor-mediated endocytosis.  
Movements in the APN ectodomain are essential for catalysis, CoV binding and cell 
infection. Blocking APN dynamics can thus prevent multiple functions associated with 
cancer and virus infections. Molecules directed to the active site that bridge APN DII and 
DIV could inhibit more efficiently APN functions; this approach open new avenues for drug 
design in APN and related aminopeptidases. Blocking ectodomain movements in the other 
CoV entry receptors could be an interesting strategy to prevent CoV infections. 
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6. CONCLUSIONS 
 
 Mammalian system such as HEK-293T and CHO cells provide a suitable platform for 
expression of membrane glycoproteins for use in protein crystallography. 
 Crystal structures of aminopeptidase N reveal ectodomain architecture, 
dimerization and conformation dynamics. 
 Domain IV mediates APN dimerization.  Its divergence among M1-aminopeptidases 
explains the different dimerization properties among members of this family. 
 The APN dimer observed in several crystal structures represents a functional 
cell membrane dimer. 
 APN crystal structures revealed the dynamic conformation of its ectodomain and they 
identified three distinct APN conformations: Open (active site at DII is accessible), 
Intermediate and Closed (active site closed by DIV). 
 Conformations of active site residues are preserved in the different APN structures.  
 The dynamic motion of the APN ectodomain likely causes peptide hydrolysis.  
 A conserved phenylalanine residue in a flexible DIV ARM repeat assists in locking 
and release of substrates during catalysis.  
 The APN open conformation is catalytically inactive. 
 Allosteric inhibition of APN functions can be accomplished by restricting 
ectodomain dynamics. 
 The crystal structure of the pig APN ectodomain has been determined in 
complex with the RBD of a porcine CoV of the genus alpha. 
 The RBD-APN complex structure defined a unique mode of receptor recognition 
among CoV; a protruding RBD tip contacts small cavities in a membrane-distal 
region of the APN ectodomain. 
 One receptor-binding motif (RBM1) in porcine and related alpha-CoV is formed by a 
-turn that exposes a tyrosine.  This residue is fully buried at the virus-receptor 
interface, and it is essential for CoV binding to APN and infection. 
 RBM1 contacts a carbohydrate N-linked to the APN, which is an important 
determinant of the CoV-host specificity. 
 RBM2 is also formed by a -turn that exposes a tryptophan.  This residue is also 
critical for CoV binding to APN and infection. 
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 RBM2 penetrates in a narrow cavity formed by APN DII and DIV.  The size of 
this cavity limits CoV binding to APN in the open conformation. 
 Conformation of the receptor-binding edge in the alpha-CoV RBD determines 
receptor-binding specificity. 
 TGEV-neutralizing antibodies target receptor-binding motifs in the S, and they 
preferentially bind either to the tyrosine in RBM1 or the tryptophan in RBM2. 
 The APN-binding region is the main antigenic determinant in the TGEV S. 
 Immune pressure likely drives evolution of receptor-specificity in CoV. 
 APN enzymatic function can be important for cell entry and infection of some CoV 
strains. 
 Targeting APN dynamics can be a new strategy towards more effective anticancer and 
anti-inflammatory agents, which should also prevent CoV infections. 
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Appendix 
TABLE A: Residues at the crystallographic interface of APN dimer. 
 
 
Buried surface areas (Å2) in the dimer interfaces of the APN structures are shown in the first row. 
APN residues from monomers 1 and 2 that interact in the dimers are on the same row. pAPN and 
hAPN interacting residues in the crystal structures are shown on the left and on the right, respectively. 
Contacts absent in specific structures are marked white in the central columns, whereas residues that 
mediate polar interactions are red. 
Determined with the PISA server (http://www.ebi.ac.uk/msdsrv/prot_int/pistart.html). 
  
  pAPN pAPNeH pAPN-
RBD 
hAPN   
Monomer1 Mon. 
2 
939 908 985 962 Mon. 
2 
Monomer1 
V835, W836  D707     D710 W839 
V835, W836, 
N839 
R708     R711 L838, W839, N842 
W836 S709     S712 W839, R843, S846 
W836, R840 E710     E713 W839, R843, S846 
W836 Y712     Y715 W839 
W836 P714     P717 E806 
E834, W836 G713     G716 E806 
Q803, D804 K717     N720 E806 
G713 Q803     E806 G716, P717, N720 
I868 N833     K836 K836, E837, I871 
K716 E834     E837 K836 
B867, I868, D707, 
R708 
V835     L838 R711, V870 
R708, S709, 
E710, V711, 
Y712, G713 
W836     W839 D710, R711, S712, 
E713, Y715, G716, 
K719 
R708 N839     N842 R711, S712 
E710 R840     R843 E713 
E710 Y844     Y847 E713 
V835 V867     V870 L838 
N833, V835, I868 
 
I868     I871 K836, I871 
P871 P871       
F910 Q875     D878 N842, Y913 
F910 Q878     Q881 Y913 
F910 S879     S882 Y913 
D875, Q878, S879 F910     Y913 D878, Q881, S882, 
Y913 
Q878, Q914 Q914     Q917 D878 
Q917 Q917       
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TABLE B: Oligonucleotide primers used in the study  
 
SNo. Identity Sequence (5’-3’) 
Aminopeptidase N 
 APN-N1 ATGGAATTCGCGTTCGACTACCTCTGG 
 APN-N2 ATGTCTAGAGCGTTCGACTACCTCTGG 
 APN-N3 TTGTCGACATGGCCAAGGGATTCTAC 
 APN-N4 GGGGAGAAGAACAAGAATGCC-3´ 
 APN-C1 TATCTAGACCGGATCCACGCGGAACCAGGCTGTGCTCTATGACCA 
 APN-C2 TCAGGATCCACGCGGAACCAG 
 APN-C3 TTTCTAGAGCCACGCGGAACCAGTTCGGAGTCGAGGAGGAA 
 APN-C4 TCAGGATCCGCTGTGCTCTATGAACCA 
 hAPN-C1 TCATGCGGCCGCTCATTTGCTGTTTTCTGTGAA 
 APN-Call TCAGCGGCCGCTCAGGATCCACGCGGAACCAG 
 APN-N738/A. ACTCTCACTAAAGCCTGGACCGAGCGC 
 APN-T7360V. ACTAAAAACTGGGTCGAGCGCCCAGAA 
 APN-E406A GACCTGTGGCTGAATGCGGGCTTTGCCTCCTATG 
 APN-HH/AA GTCACTGTGATTGCTGCCGAGCTGGCCGCCCAGTGGTTTGGCAAC 
 APNV835T TGCAGCAACGAGACCTGGCTCCTGAAC 
Coronavirus Spike  
 CoS-N1 TT GTCGACATGAAAAAACTATTTGTGG 
 CoS-N2 ATGTCTAGAAATAACATTAAATGCTCT 
 CoS-N3 ATGTCTAGAACTGCTAATTTGAATAAT 
 CoS-N4 ATGTCTAGATTACTACCTAGCTTTTAC 
 CoS-C1 TCAGGATCCACGCGGAACCAGATTACCAGTGCTAATTGG 
 CoS-C2 TCAGGATCCACGCGGAACCAGGCCATTATAGTATTGAGC 
 CoS-C3 TCAGGATCCACGCGGAACCAGCACTATGTTGTCTCCTTC 
 CoS-C4 TCAGGATCCACGCGGAACCAAATTAAAAGATATACA 
 CoS-C5 TCAGGATCCACGCGGAACCAGAATGACGTCTACAGTGTT 
 Cos-C32 TCAGGATCCACGCGGAACCAGATTATCAGACGGTACACC 
 R525A CTTGGTATGAAGGCGAGTGGTTATGGT 
 G527D. ATGAAGCGTAGTGATTATGGTCAACCC 
 Y528A. CGTAGTGGTGCTGGTCAACCC 
 G529D. AGT GGTTATGATCAACCCATAGCC 
 Q530A. AGTGGTTATGGTGCACCCATAGCCTCA 
 I532A. TAATGTTGAGGCTGCGGGTTGACCATA 
 L570A. TGCAAAAGTTCTGCATGGGACAATATT 
 W571A. GCAAAAGTTCTTTAGCGGACAATATTTTTAAGC 
 LWD572A. TGC AAA AGT TCT GCC AAT ATT TTT AAG CGA 
 DV582AA. CGA AAC TGC ACG GCC GCT TTA GAT GCC ACA 
 V617A TCGTTGAGTCCTGATGGTGCTATTGT 
 V617D TCGTTGAGTCCTGATGGTGCTAATTGT 
 R630A. GCT GCC CGT ACA GCT ACC AAT GAG CAG 
 TN632AA. GCC CGT ACA AGA GCC GCT GAG CAG GTT GTT 
 N632A. CGTACAAGAACCGCTGAGCAGGTTGTT 
 Q634A. AGAACCAATGAGGCGGTTGTTAGAAGT 
 NQ634AA. CGTACAAGAACCGCTGCGGCGGTTGTTAGAAGT 
Miscellaneous 
 pEF-1a TCAAGCCTCAGACAGTGGTTC 
 pEF-R CTCTCAAGGGTCCCAGGT 
 ClaI-4829 AACAGACACACGTTCATGG 
 ClaI-4310 CTTTTATCAGGGTGCTTTGG 
 
